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Abstract 
EFFECTS OF HIV-1 VIRAL PROTEIN TAT ON THE VIABILITY AND FUNCTION OF 
OLIGODENDROGLIAL CELLS 
By ShiPing Zou, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctorate in Philosophy in Neuroscience at Virginia Commonwealth University. 
Virginia Commonwealth University, 2015 
Major Director: Pamela E. Knapp, Ph.D., Professor of Anatomy and Neurobiology 
 
 
Myelin pallor is frequently reported in HIV patients, and can occur in the CNS prior to 
other evidence of disease process. Our exploratory studies showed that 
oligodendrocytes (OLs) are direct targets of HIV-1 Tat (transactivator of transcription). 
Tat induces a dose-dependent increase of intracellular Ca2+ level ([Ca2+]i) in cultured 
murine OLs, which can be attenuated by ionotropic glutamate receptor (iGluR) 
antagonists MK801 and CNQX. The Tat-induced [Ca2+]i increase leads to increased 
death in immature (O4+, MBP-), but not mature (O4+, MBP+) OLs, over 96 h. In addition, 
Tat-induced [Ca2+]i increase also reduced myelin-like membrane production by mature 
OLs. Calcium/Calmodulin dependent kinase IIβ (CaMKIIβ) and glycogen synthase 
kinase 3β (GSK3β) have been known to regulate differentiation, myelination,
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and apoptosis in OLs. Since both CaMKIIβ and GSK3β are important downstream 
modulators of [Ca2+]i change, we hypothesized that the detrimental effects of Tat on 
immature/mature OL viability and function are mediated via CaMKIIβ and GSK3β 
activation. Our results showed that Tat activates both CaMKIIβ and GSK3β in immature 
OLs, but only activates CaMKIIβ in mature OLs. MK801 completely blocks Tat-induced 
CaMKIIβ and GSK3β activation in both immature and mature OLs, while CNQX blocks 
GSK3β activation, but has only a partial effect on CaMKIIβ activity. Blocking iGluRs or 
inhibiting GSK3β both rescue Tat-induced immature OL death, but only MK801 reverses 
the membrane injury in mature OLs. Together, these data strongly suggest that 1) 
activity of CaMKIIβ and GSK3β in OLs can be regulated by Tat-induced iGluRs 
activation and 2) OLs at different developmental stages show different responses to Tat, 
possibly due to activation of different signaling pathways. 
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Chapter 1 
Introduction to HIV-1 and WM injury in the Central Nervous System 
 
HIV-1 and AIDS Overall 
HIV is a member of the lentivirus family. There are two types of HIV: HIV-1 and 
HIV-2. Although both types infect cells in similar ways and appear to cause clinically 
indistinguishable AIDS, studies showed that HIV-1 is the predominant virus type. 
Infections of HIV-2 are: 1) rarely found outside of West Africa (de Silva et al., 2008), and 
2) seldom progressed to AIDS or lead to HAND (Rowland-Jones and Whittle, 2007). On 
the other hand, more than 34 million individuals were infected by HIV-1 by the end of 
2009 (UNAIDS, 2010). Currently, four strains of HIV-1 have been identified: the major 
group M, the outlier group O and two new groups N and P. At least 9 genetically distinct 
subtypes, designated as clades A, B, C, D, F, G, H, J and K, were found in group M, 
which accounts for >90% of HIV-1 infection. Recombinant forms of HIV-1 were also 
discovered from individuals infected with multiple subtypes of HIV-1. Some of the 
recombinant forms were reported to be transmitted between individuals, thus called 
circulating recombinant forms. Among all the HIV-1 clades, clade B is the most 
prevailing subtype that affects America, most of Europe and Australia (Gilbert et al., 
2007).  
The single-stranded RNA genome of HIV-1 encodes nine proteins consisting of 
envelope (Env), core (Gag), polymerase (Pol) and six accessory proteins including Tat 
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and Nef. The first step of HIV infection is the binding of the viral envelope protein gp120 
to the CD4 receptors on the surface of the host cell (Sattentau et al., 1986). This binding 
induces a conformational change in gp120, which exposes its binding site to its cellular 
co-receptors. CCR5 and CXCR4, two receptors first identified as CC- and CXC- 
chemokine receptors, respectively, are the most reported co-receptors for HIV infection. 
Other chemokine receptors, including CCR2, CCR3, and CX3CR1 have also been 
reported to be utilized by HIV as co-receptors (He et al., 1997; Garin et al., 2003; 
Puissant et al., 2003). The Interaction between gp120 and these co-receptors triggers 
further conformational change and the insertion of HIV-1 gp41 into the host cell 
membrane, which initiates the fusion of the membranes and eventually leads to the 
entry of the virus genome and proteins. Once the host cell is infected, the viral reverse 
transcriptase makes viral DNA using its RNA genome template. The newly synthesized 
viral DNA binds to the viral protein integrase and some host proteins to form the pre-
integration complex, which then translocate to the nucleus, integrate into the host 
genome, and form the provirus. Infected cells can either be latent, or actively transcribe 
and produce virus and viral proteins such as Tat, gp120, Nef and Vpr. 
The first case of HIV infection in the United States can be dated back to the 
1970s, and AIDS was reported in New York and California in the 1980s. By 1983, 
approximately 3000 AIDS patients had been reported and 1000 patients had died 
(Berkson, 1990). Over 33 million individuals are currently infected by HIV (Power et al., 
2012), and CDC estimates 50,000 Americans becoming infected with HIV each year. 
Since the first case of HIV infection, nearly 619,400 people had died with AIDS. The 
development of cART in 1996 has dramatically decreased the incidence of mortality and 
		 5	
initial progress of neurological pathogenesis, but it had little effects on HAND, which is 
estimated to affect 60% of the HIV infected population (Williams et al., 2009). Until 
today, AIDS is still the most common cause of dementia in non-aged individuals in the 
US. Thus, CNS neuropathology, such as HIV-associated dementia and moderate 
cognitive and motor diseases, remains a serious issue in HIV patients.  
 
CNS dysfunction and WM neuropathology in HIV 
Although the initial HIV infection occurs in the periphery and targets CD4+ 
lymphocytes, HIV enters the CNS at early, asymptomatic stages (Kramer-Hammerle et 
al., 2005). There are multiple ways by which HIV penetrates the BBB and enter the 
CNS. The major components of the BBB, microvascular endothelial cells, have been 
reported to be infected by HIV-1, which leads to trans-cellular migration of the virus into 
the CNS (Bagasra et al., 1996). Alternatively, infiltrated macrophages carrying HIV-1 as 
provirus may release HIV-1 in the CNS (Merrill and Chen, 1991). Further, infection-
induced inflammation has also been shown to disrupt the integrity of the BBB, which 
may facilitate the CNS entry of virus and infected cells (Eugenin et al., 2011). 
 A large retrospective study in 2000 using 450 AIDS autopsy cases between 
1984 and 1999 found that the brain was second only to lung in HIV-induced pathology, 
with 39% to 70% of all AIDS patients developing neurological disorders (Jellinger et al., 
2000; Maschke et al., 2000). Clinically, HIV-associated dementia and other HIV-induced 
brain injuries have been demonstrated by CT scans and MRI images. A study of HIV-
infected children by Roy et al., (1992) reported that all of the 49 patients participating in 
the research exhibited cerebral WM atrophy on their CT-scans. Jernigan et al., (1993)          
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later compared structural MRI images of HIV+ patients with HIV- individuals. Their 
results suggested that HIV+ patients, with or without clinical symptoms, showed 
preferential damage to cerebral WM and subcortical brain structures. This is in 
agreement with Stout et al., (1998),   who also reported that HIV+ males had a more 
rapid loss of the cortical tissues than HIV- males, and the reduction in WM volume was 
accelerated in patients with clinical symptoms than those asymptomatic patients.  
Myelin pallor is an abnormal appearance of WM in histological sections that 
indicates myelin and oligodendroglia injury. Although it is clinically considered as non-
specific WM pathology and has been attributed largely to edema resulting from 
inflammation-mediated changes in the blood brain barrier, it is among the most 
frequently reported change in HIV patients, and can occur in the CNS prior to other 
evidence of a disease involvement. In the brains of HIV+ patients, microgliosis and 
astrogliosis are significantly correlated to myelin pallor (Esiri et al., 1991). HIV-induced 
microgliosis and astrogliosis have been observed in patients and reported together with 
elevated levels of TNF-α and p24 antigen repeatedly (Gyorkey et al., 1987; Eilbott et al., 
1989; Esiri et al., 1991). Infected microglial cells and infiltrated macrophages secrete 
pro-inflammatory cytokines and chemokines such as TNF-α, IL-1β, IL-6, IFN-γ, MCP-1, 
MIP-1α and CXCL10 (Tyor et al., 1992; Sui et al., 2004; Herbein et al., 2010), together 
with HIV viral proteins, including Tat, Nef and gp120, which not only show direct toxicity 
to myelin and oligodendroglia but also dysregulate receptor and cytokine/chemokine 
expression on CNS cells (Sui et al., 2004). Some of the secreted viral proteins are also 
chemoattractants (Albini et al., 1998a; Albini et al., 1998b), and can function in concert 
with chemokines to attract more reactive astroglia and microglia to the lesion site. Viral 
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proteins like Tat and gp120 can induce production of toxic factors (Lipton, 1998; Nath 
and Geiger, 1998; Hurley et al., 2003) and ROS (Chauhan et al., 2003; King et al., 
2006) from infected glial cells, as well as stimulate further viral replication and 
production. Collectively, dysregulated cytokine and chemokine levels (El-Hage et al., 
2008b), increased ROS production (Viviani et al., 2001), cluster of multinucleated giant 
cells (Esiri et al., 1991) and decreased glutamate uptake (Wang et al., 2003) in the CNS 
of HIV+ patients may lead to HIV-encephalitis, which happened in 10-50% of HIV 
patients (Bell, 1998) and is characterized by reactive gliosis, myelin pallor and infiltration 
of multinucleated giant cells (Wiley et al., 1991). HIV-encephalitis is frequently 
associated with WM damage ranging from inflammatory to degenerative pathology. 
Studies using multiple imaging, immunocytochemistry and biochemical techniques have 
shown that a number of WM diseases, such as progressive multifocal 
leukoencephalopathy (Zanin et al., 2012), cytomegalovirus encephalitis (Bell, 1998) and 
vacuolar myelopathy (Tan et al., 1995), are all linked to HIV infection.  
Together, these findings suggest that HIV infection causes progressive atrophy 
within the WM in the brain, and injuries to the WM were most severe in the advanced 
stages of disease but were also evident even in asymptomatic HIV-positive persons. 
 
OLs and myelin injuries in HIV 
Cells of the immune system and CNS are known to be the main targets of HIV 
(Fauci, 1988; Price et al., 1988). Microglia and infiltrating macrophages are the major 
productively infected cells in the CNS (Jordan et al., 1991; Merrill and Chen, 1991). 
Astroglial infection by HIV via a CD4-independent mechanism has been reported (Liu et 
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al., 2004). However, infected astrocytes are rarely found in AIDS patients, and produce 
newly assembled viral particles at very low levels (Gorry et al., 2003; Kramer-Hammerle 
et al., 2005). The cells in the CNS that are most vulnerable to HIV infection are neurons 
and OLs. OLs are the CNS cells whose main function is to maintain the myelin that 
wraps around the axon to ensure saltatory propagation of action potentials. In addition, 
OLs have also been shown to regulate outgrowth and regeneration of central neurons 
(Bastmeyer et al., 1991; Schwab and Schnell, 1991). OLs do not express the CD4 
receptor. However, several research groups have shown that galactosylceramide 
(GalCer), a glycolipid that is highly expressed on the surface of OLs, can serve as an 
alternative receptor that mediates HIV infection (Harouse et al., 1991; Yahi et al., 1992; 
Albright et al., 1996). Hence, whether OLs are infected by HIV or not remains elusive. 
On the other hand, OL injuries in HIV+ CNS were frequently reported. Gyorkey et al., 
(1987) found hyperplasia of OLs followed by degeneration in brain biopsies of AIDS 
patients. This may be one of the first published pieces of data suggesting HIV-infection 
has pathological effects on oligodendroglial cells in the brain. Similar results were also 
reported by Esiri et al., (1991) who examined CNS tissues from spinal cords of 22 HIV-1 
infected individuals and 11 HIV- controls and concluded that HIV-1 infection leads to an 
increased number of oligodendroglial lineage cells with or without severe myelin pallor, 
suggesting OL injures may precede myelin damage. More recent studies reported that 
OLs from post-mortem HIV tissues show up-regulated expression of p53 and BAX 
(Jayadev et al., 2007), indicating activation of death pathways. Approximately one-
fourth of the patients that have died of AIDS showed a characteristic vacuolar 
myelopathy at autopsy (Eilbott et al., 1989). MBP immunostaining using tissues from 
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these patients revealed signs of demyelination as well as presence of MBP 
fluorescence in the cytoplasm of the macrophage, suggesting damage of myelin, and 
possibly also OLs, leading to their subsequent phagocytosis by infiltrated macrophages 
(Eilbott et al., 1989). All these studies suggested that although proof of OL infection by 
HIV is limited, OL and myelin impairment in AIDS patients are common. Even if the 
infection itself is unlikely to be the major cause of OL injury, CNS infection by HIV has 
direct or indirect effects on OLs. 
 
HIV-1 Tat 
Infected microglia/macrophages express all nine viral proteins that are encoded 
by the HIV genome. For the purpose of this thesis project, I will focus on HIV-1 Tat. Tat 
is a virally encoded transactivator that is conserved in the genomes of primate lentivirus. 
It is synthesized at both early and late stages of viral replication, and is essential for 
efficient transcription of HIV viral genes and for HIV replication. Extracellular Tat has the 
strong tendency to adhere to the surface of nearby cells. In addition, it accumulates in 
the extracellular matrix via interaction between its basic domains and heparin sulfate 
proteoglycans (HSPGs) (Chang et al., 1997). Tat also has the CCF motif, which mimics 
the CC-chemokines that attracts CCR2, CCR3 and CXCR4 expressing glial cells 
(Cardona et al., 2006). The mRNA of the Tat protein consists of two coding exons. The 
first exon encodes amino acids 1–72, and the second exon encodes amino acids 73–
101. The recombinant Tat used in most research laboratories was a truncated version 
of amino acids 1-86. The full-length Tat protein contains five functional domains: the N-
terminal domain; the cysteine-rich domain that contains a CCF motif which competes 
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with cognate ligands to bind CXCR4, CCR2 and CCR3 chemokine receptors (King et 
al., 2006); the core region and the basic region that possesses the neurotoxicity of Tat 
as well as a nucleus localization sequence (NLS) (Albini et al., 1998b); and the C-
terminal domain contains an RGD motif that mediates its interaction with the integrin 
receptor (Chang et al., 1997; Albini et al., 1998a). Although the demarcation of these 
five domains is somewhat arbitrary, it is generally accepted that the first four domains 
were included in the first exon and the fifth domain was encoded by the second exon. 
Tat has been reported to induce a series of cellular responses in variable CNS 
cells. Tat induces expression of CCR3, CCR5 and CXCR4 in monocytes and 
macrophages in a concentration-dependent manner (Cardona et al., 2006). Since the 
CCF motif of Tat binds to β-chemokine receptors, up-regulation of these receptors 
facilitates a chemotactic response to Tat (Lafrenie et al., 1996). Tat has also been 
reported to cause increased [Ca2+]i either in a concentration-dependent manner through 
chemokine receptors (Albini et al., 1998b) or iGluRs (Song et al., 2003), or by activating 
the PLC, protein kinase C (PKC) and Gi/o protein pathway, which in turn opens IP3-
gated intracellular Ca2+ stores (Power et al., 1998). The Tat-induced Ca2+ signaling in 
macrophages results in the production of pro-inflammatory cytokines and chemokines 
such as TNF-α, IL-6, TNF-β and TGF-β, as well as the cytokine receptor IL-4 receptor 
(IL-4R) (Puri and Aggarwal, 1992), which leads to inflammation and neuropathogenesis. 
Tat also increases production of free radicals in microglia. It has been shown that the 
Tat-induced expression of NO and iNOS is enhanced by IFN-γ, which is also elevated in 
the CNS of HIV/AIDS patients, suggesting a cooperative contribution between Tat and 
IFN-γ towards CNS injury (Polazzi et al., 1999). cAMP accumulation in microglia has 
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been known to induce expression of neuroprotective or immunosuppressive substances 
(Aloisi et al., 1999). Tat treatment decreases cAMP levels in microglial cultures in a 
dose- and time-dependent manner (Aloisi et al., 1999), indicating that Tat interferes with 
cAMP control of microglial activation. Tat also activates astrocyte production of pro-
inflammatory cytokines and chemokines (El-Hage et al., 2008b; Zou et al., 2011b). 
Astrocytes exposed to Tat exhibit increased IκBα phosphorylation, followed by NFκB 
phosphorylation and nuclear translocation, and increased production of TNF-α, MIP-1 
and IL-6 (El-Hage et al., 2008b), indicating activation of astroglial inflammatory 
responses. Tat has also been shown to cause increased production of free radicals and 
ROS in rat OLs, which leads to decreased glutathione (GSH) levels and increased lipid 
peroxidation (LPO), and eventually causes OL process retraction and apoptosis 
(Rathnasamy et al., 2011; Fernandez-Gamba et al., 2012).  
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Chapter 2 Effects of HIV-1 Tat on OLs in vivo 
 
(This chapter, in part, was published as a paper in the Journal of Neuroscience in 
August of 2015, 35(32):11384-11398, entitled Oligodendrocytes are targets of HIV-1 
Tat: NMDA and AMPA receptor-mediated effects on survival and development) 
 
Introduction 
Although combined anti-retroviral therapy (cART) dramatically decreases 
mortality and neurological deficits, 60% of the HIV-infected population still experience 
HIV-associated neurocognitive disorders (HAND) (Williams et al., 2009; Power et al., 
2012). Despite viral suppression, infected brain cells, including microglia and astrocytes, 
continuously express and secrete viral proteins. Tat is a highly conserved HIV protein 
that can be detected in the blood (Xiao et al., 2000), extracellular matrix (Urbinati et al., 
2005a), and cerebrospinal fluid (Wang et al., 2014) in HIV+ individuals, even with cART 
(Johnson et al., 2013). Besides its essential role in viral replication and efficient viral 
gene transcription, Tat has also been shown to be a toxic factor in the central nervous 
system (CNS) that leads to glial inflammatory responses (Nath et al., 2000; El-Hage et 
al., 2006; El-Hage et al., 2008a) and neuronal cell death (Zou et al., 2011b; Rumbaugh 
et al., 2013). 
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Oligodendrocytes (OLs) are myelinating CNS cells. OL dysfunction can lead to 
abnormal myelination, impaired neuronal signaling, and axon degeneration, resulting in 
serious neurological deficits. Tat-induced inflammatory response from astroglia or 
microglia may lead to OL injury. For example, TNF-α released from Tat-challenged 
astroglia has been shown to activate caspase-3 and induce apoptosis in both pre-
myelinating and mature oligodendrocytes in rats (Rathnasamy et al., 2011). IL-1β, which 
is released by Tat-treated microglia, inhibits proliferation of rat oligodendroglial 
precursor cells (Kaur et al., 2012).  Thus, WM injury in HIV+ patients may be attributed 
to Tat-induced glial inflammatory responses, which concurrently activates OL death 
signaling pathways and inhibits OL precursor cell proliferation. 
Besides inflammation, Tat may also injure OLs via more direct mechanisms. OLs 
express variable surface molecules, including chemokine receptors CXCR4 (Patel et al., 
2010), ionotropic (Salter and Fern, 2005) and metabotropic (Matute, 2011) 
glutamatergic receptors, integrin receptors (Laursen and Ffrench-Constant, 2007) and 
voltage-gated calcium channels (Kirischuk et al., 1995). These molecules have all been 
reported to interact with Tat in neurons (Diop et al., 1994; Albini et al., 1998b; Song et 
al., 2003; King et al., 2006; Li et al., 2008). The interactions between Tat and these 
molecules may underlie the mechanisms of direct effects of Tat towards OLs, which 
have not been extensively studied.  
Early studies using Tat-transgenic mice showed that OLs exhibit caspase-3 
activation and decreased process length when Tat expression was induced for 7 days 
(Hauser et al., 2009), suggesting that Tat may affect OLs morphology and function in 
vivo. The Tat-transgenic mouse was engineered to inducibly express HIV-1IIIB Tat1-86. In 
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these mice, Tat expression is controlled by a tet responsive element, whose activation 
is controlled by a reverse tetracycline transactivator (rtTA) transgene driven by a human 
glial fibrillary acidic protein (GFAP) promoter (Hauser et al., 2009; Hahn et al., 2012). 
Within the CNS, Tat expression is induced in astroglia by administration of DOX. 
Current studies use the same Tat-transgenic mice to systematically assess the effect of 
Tat on OLs. Using the Golgi–Kopsch procedure, we observed an increased occurrence 
of OLs with aberrant morphology in the corpus callosum and anterior commissure of 
transgenic mice expressing HIV-1 Tat for 7 days. Disrupted myelin structure was 
observed in the caudate putamen by electron microscopy after a longer Tat expression 
(12 wk). Western blot analysis of tissues from the same mice (12 wk Tat induction) 
show decreased expression of myelin protein MBP and MAG when compared with their 
Tat- littermate fed with DOX-containing chow. Together, these observations indicating 
that expression of Tat in vivo leads to OL injury at cellular, subcellular and protein 
levels. Further studies are needed to tell whether these OL injuries come from an 
inflammatory response or direct Tat toxicity. 
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Materials and Methods 
All experiments involving animals were performed in compliance with procedures 
reviewed and approved by the Virginia Commonwealth University Institutional Animal 
Care and Use Committee (IACUC). 
 
Tat transgenic mice and in vivo Tat expression 
This study utilized a transgenic mouse engineered to inducibly express HIV-1IIIB 
Tat1-86. Tat expression is controlled by a tet responsive element, whose activation is 
controlled by a reverse tetracycline transactivator (rtTA) transgene driven by a human 
glial fibrillary acidic protein (GFAP) promoter (Hauser et al., 2009; Hahn et al., 2012). 
Within the CNS, Tat expression is induced in astroglia by administration of DOX. HIV 
transgenic (Tat+) and Tat- control littermates were fed DOX-containing chow (6g/kg; 
Harlan Laboratories, Inc., Indianapolis, IN) ad libitum to induce expression of Tat. Both 
acute and chronic time periods were chosen for Tat induction to visualize early changes 
in OL processes (Golgi impregnation, 7 d) that might precede later myelin changes (EM, 
12 wk) in Tat+ mice. The Tat- mice express rtTA, but not Tat, and are a control for 
possible effects of the foreign transcription factor. The expression of the rtTA transgene 
in Tat- mice and rtTA and Tat transgenes in Tat+ mice was confirmed by genotyping. 
The OL and myelin injury was observed in three different CNS regions (EM: caudate 
putamen; Golgi-impregnation: corpus callosum and anterior commissure), our studies 
were not designed to determine if defects were region specific. 
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Western Blotting 
Striatal tissue from Tat transgenic mice was homogenized with 3 strokes (15 
s/stroke) in a 2 ml ceramic bead tube (MO BIO Laboratories, Carlsbad, CA) using a 
Precellys 24 Homogenizer (Bertin Technologies, Rockville, MD) before protein 
extraction using RIPA buffer with protease and phosphatase inhibitors. The 
concentration of extracted proteins was assessed using the BCA assay (Thermo 
Scientific) before lysates were mixed at 1:1 ratio with 2x Laemmli buffer (BioRad, 
Hercules, CA). Equal amounts of total protein (5 - 10 µg) from each sample were loaded 
on Criterion 4–20% SDS-polyacrylamide gels (BioRad) and electrophoretically 
separated under constant voltage (130 V) for 1.5 h. Proteins were then transferred onto 
polyvinylidene difluoride (PVDF) membranes (BioRad) with constant current (0.6 A, 2 h, 
4°C). After transfer, membranes were blocked in 0.1% casein solution (BioRad, 1 h, 
room temperature) before probing with primary antibodies for MBP (1:5000, Abcam), 
MAG (1:3000, Abcam), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
1:3000, Abcam) at 4°C overnight. Membranes were incubated with appropriate IRDye 
secondary antibodies (1:3000, Li-COR, Lincoln, NE) for 1 h at room temperature, and 
imaged using an Odyssey Imager (Li-COR). Protein bands were quantified using Li-
COR image studio software.  
 
Electron Microscopy 
Tissue processing and EM were performed as previously published (Hahn et al., 
2012). In brief, Tat+ mice fed with DOX-containing chow for 3 months were perfused 
with phosphate buffer (pH=7.4, Sigma) containing 2% paraformaldehyde and 2% 
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glutaraldehyde before fixation/staining in 1% osmium tetroxide for 1 h. Fixed tissues 
were dehydrated through graded ethanols and infiltrated overnight in Embed 812 (EMS, 
Hatfield, PA), then polymerized at 60 °C for 2 d. Tissue blocks were sectioned at 600 – 
700 Å thickness on a Leica EM UC6i ultramicrotome (Leica Microsystems), collected 
onto formvar-coated grids, and stained with uranyl acetate (5%) and Reynolds’s lead 
citrate (Reynolds, 1963). EM images were taken with a JEOL JEM-1230 Transmission 
Electron Microscope (JEOL USA, Inc. Peabody, MA) at 10,000—200,000x 
magnification using a Gatan Ultrascan 4000 digital camera with DigitalMicrographTM 
software (Gatan Inc., Pleasanton, CA). 
 
Golgi–Kopsch Impregnation 
12-wk old Tat transgenic mice received normal (Tat-) or DOX-containing chow 
(Tat- and Tat+) for 7 d. A modified Golgi-Kopsch procedure as previously published 
(Hauser et al., 1989) was used to randomly impregnate neurons and glia. In brief, mice 
were anesthetized by isoflurane inhalation and euthanatized by intracardiac perfusion 
with 2% potassium dichromate and 5% glutaraldehyde. Whole forebrains were taken 
out, immersed in perfusion solution for 5 d before rinsed and re-placed in aqueous 
0.75% silver nitrate solution for another 5 d. After that, tissues were infiltrated with 
graded sucrose solutions containing 0.75% silver nitrate for 24 h and frozen on dry ice 
before cutting into 120-µm thick serial coronals sections and thaw-mounting onto 
Superfrost-Plus slides (Fisher). Fluid to tissue volume ratios were ≥ 50:1, and non-
metallic devices were used throughout. Images of impregnated OLs were taken 
randomly from corpus callosum and anterior commissure. Impregnated OLs were 
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identified using strict morphological criteria, including small (~10 µm diameter) cell body, 
myelin-forming processes aligned parallel to WM tracts, and appropriate localization. 
For each experimental condition (Tat-, Tat- + DOX and Tat+ + DOX), 4 mice were used 
(N=4) and at least 40 cells were examined per mouse. 
  
		 19	
Results 
Oligodendrocyte morphology in Tat transgenic mice 
Fibrous astrocytes and OLs, the major cell types with cell bodies in the corpus 
callosum and anterior commissure, can be easily distinguished from each other in 
Golgi-Kopsch impregnated sections by their distinct morphologies. Significantly more 
OLs with abnormal morphology, including stunted or swollen processes, large (several 
microns in diameter), club-like cytoplasmic endings, and aberrant cell bodies were 
noted in Tat+ mice when compared with their Tat- siblings with/without DOX (Fig. 2.1). 
 
Ultrastructure of Tat+ mice 
We next asked whether Tat induction by DOX caused any injury at the 
subcellular level in the transgenic mice. Electron microscopy revealed that many OLs in 
Tat+ mice had a seemingly normal morphology and subcellular structure after a 3-month 
DOX induction (Fig. 2.2A), yet a subpopulation showed very clear deficits. Enlarged 
periaxonal collars with dark cytoplasm were relatively common, potentially indicating 
accumulation of periaxonal fluid due to a deficit in exuding ion/fluid in OLs (Byun and 
Delpire, 2007) (Fig. 2.2B, C, E). Myelin splitting was also common, and associated with 
both normal-appearing axons (Fig. 2.2C, D, M-P) and axons exhibiting increased 
axoplasmic density (Fig. 1.2E). Abnormal membranous structures, and membrane 
inclusions with apparent periodicity were often observed (Fig. 2.2D-F, H), indicating 
potential deficits in OL membrane turnover. Hypomyelinated axons (1.D, N) and myelin 
membranes without an associated axon were also noted (Fig. 2.2J, L).  
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Tat Expression leads to down-regulated myelin proteins in vivo 
A deficiency in myelin associated glycoprotein (MAG), which mediates axon-glial 
contact, has been reported to cause enlarged periaxonal collars (Trapp et al., 1984; 
Montag et al., 1994); and decreased levels of myelin basic protein (MBP) are often 
found in transgenic mice with myelin defects (Popko et al., 1987; Imgrund et al., 2009). 
We thus examined the expression level of MAG and MBP in Tat transgenic mice. 
Western blots of lysates from striatum showed that Tat+ mice exhibit significantly 
decreased levels of MAG and MBP when compared with their Tat- littermates after 3-
month DOX-induction (Fig. 2.3). 
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Discussion 
We found from these in vivo studies that transgenic mice with inducible Tat 
expression had higher numbers of OLs with an abnormal phenotype in Golgi-
impregnated cells, disturbances in myelin ultrastructure, and decreased myelin protein 
(MBP and MAG) expression. 
Tat transgenic mice were separated into three treatment groups. Group 1: Tat- 
mice fed with normal diet without Dox; Group 2: Tat- mice fed with DOX-containing 
chow; and Group 3: Tat+ mice fed with DOX-containing chow. While comparisons 
between group 2 and group 3 show the effects of in vivo Tat expression on OLs, group 
1 serves as a control for non-specific effects of DOX intake. As Fig 2.1 showed, no 
differences were found between group 1 and group 2, suggesting the effects on OL 
morphology are unlikely to be caused by DOX. 
We chose the anterior commissure and the corpus callosum as the two areas of 
interest, since Goigi-impregnation cannot be performed concurrently with other 
procedures (e.g. immunostaining) to discern different cell types. The anterior 
commissure and corpus callosum are the two prominent white matter tracts that can be 
unambiguously distinguished from other functional areas in brain sections. In addition, 
the majority of CNS cells with cell bodies residing in WM are fibrous astrocytes and 
OLs. A series of morphological criteria that was defined in previous studies (Hauser et 
al., 2009) were used to differentiate these two cell types from each other. In these two 
brain regions, OLs are easily discernable by their small soma size (~10 µm in diameter), 
outreaching processes that are parallel to myelinated axons, and appropriate location 
(associated with white matter bundles).  
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Our result suggested that inducing Tat expression for 7 days significantly 
increased the occurrence of OLs with abnormal morphology in the corpus callosum and 
anterior commissure. It is worth pointing out that the OLs we counted were mature, 
myelinating OLs, characterized by myelinating processes attached to the axon tracts. 
Migrating OPCs that rise from the subventricular zone can also be found in white matter 
tracts. Due to the restriction of this method, however, we are not able to unambiguously 
identify OPCs by its morphology. 
We next investigated whether Tat expression also leads to injuries in myelin 
structure. Multiple abnormalities, including enlarged periaxonal collar, myelin splitting, 
hypomyelinated axons, abnormal membranous bodies, and the inclusion of myelin-like 
membranes, were found in the caudate putamen of Tat+ mice by EM (Fig. 2.2). Among 
these aberrant structures, enlarged periaxonal collars and split myelin have been the 
most frequently observed. In the peripheral nervous system, the formation and 
maintenance of the regular periaxonal collar requires the presence of MAG in the 
Schwann cell periaxonal membrane (Trapp et al., 1984). On the other hand, uncompact 
myelin lamellae have been found in the brain of myelin deficient mice (mld) that lack 
MBP expression (Matthieu, 1981). We thus tested the expression of MBP and MAG in 
the CNS of these mice. Consistent with our EM observation, western blot results 
showed significantly decreased expression of MAG and MBP in the brain of Tat+ mice 
compare to Tat- mice (Fig. 2.3). 
Multiple cellular abnormalities have been reported in Tat-transgenic mice, 
including reactive astrogliosis and microgliosis (Bruce-Keller et al., 2008), elevated 
caspase-3 activation in OLs (Hauser et al., 2009), and synaptodendritic injury (Kim et 
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al., 2003; Fitting et al., 2014), which coincide with deficits in behavior including learning 
and memory (Carey et al., 2012; Fitting et al., 2013) and cognitive/motor impairments 
(Hahn et al., 2015). Here, our in vivo studies showed that Tat also caused myelin 
damage and OL injury. Most previous studies suggest Tat-induced inflammation as the 
predominant cause of CNS injury. However, controlled trials of cART with adjunctive 
'anti-inflammatory' agents do not show greater efficacy against HAND than cART alone 
(Tan and McArthur, 2012), suggesting neurotoxic effectors besides inflammation. We 
next used a highly purified culture system (>90% OLs) as our in vitro model to further 
elucidate whether there is a direct Tat toxicity to OLs.  
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Figure 2.1 
 
 
Figure 2.1. Tat induces aberrant OL morphology in vivo. Golgi-Kopsch impregnation 
was used to visualize the structure of OLs in Tat- mice receiving normal chow, and in 
Tat- and Tat+ mice fed DOX-containing chow for 7 d. Sample brightfield images (A-H) 
are labeled with the genotype and treatment. (A-E) The majority of OLs from corpus 
callosum and anterior commissure of Tat- mice fed normal or DOX-containing chow 
show normal morphology. These OLs have small (~10 µm diameter) cell bodies with 
smooth edges and relatively thick and continuous processes extending from their cell 
body to the white matter tracts. (F-H) Although most OLs in DOX-induced Tat+ mice 
appear normal, a significantly higher percentage had an aberrant phenotype. These 
OLs exhibited abnormal varicosities along or at the end of their processes 
(arrowheads), thin and disrupted processes, and irregular cell bodies (arrows). (I) 
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Quantification of OLs with abnormal morphology in the corpus callosum and the anterior 
commissure of Tat- and Tat+ mice. In both regions, Tat induction resulted in significantly 
more OLs with pathological phenotype. (*p<0.05; one-way ANOVA followed by post-hoc 
Bonferroni’s test; n=4 individual experiments; >40 cells were counted for each n; scale 
bar = 10 µm for all images). 
  
		 26	
Figure 2.2 
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Figure 2.2 Ultrastructural examination of caudate putamen in Tat+ mice. (A) Even 
after 3 months of continuous Tat expression, most OLs show a normal phenotype and 
subcellular structure (G: Golgi apparatus; RER: rough endoplasmic reticulum). (B-P) 
Despite this observation, multiple abnormal structures were commonly observed and 
documented in a subset of Tat exposed OLs. These include: i) Enlarged periaxonal 
collars containing dark cytoplasm (black arrows in B, C & E), possibly due to 
accumulation of periaxonal fluid; ii) Myelin splitting, suggesting a potential deficit of 
myelin compaction, is found both with normal-appearing axons (M, O, P; arrowheads in 
C, D, N) and axons exhibiting an abnormally dense cytoplasm (arrowhead in E); iii) 
Abnormal membranous structures (white arrows in D, E) and myelin-like membrane 
inclusions with obvious periodicity (F, H), indicating potential deficits in OL membrane 
turnover; iv) Hypomyelination, as indicated by axons of similar calibers in the same 
region invested with myelin sheaths of different thickness (N, compare axon groups a, 
b, c vs. a*, b*, c*, respectively). Also, in D, the axon denoted with # is unmyelinated, 
while neighboring axons with similar diameters have normal compact myelin; v) Axons 
with an abnormally dense cytoplasm, (Ax in E) and a myelin membrane in the absence 
of an axon, (J, L) were also noted. 
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Figure 2.3 
 
 
Figure 2.3. In vivo Tat expression leads to decreased MBP and MAG. Western blot 
analysis of tissue lysate from transgenic mice after 3 month Tat induction showed 
decreased levels of both MBP and MAG. Protein expression was normalized to 
GAPDH. (n=4, Values are mean ± SEM; *p<0.05, t-test) 
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Chapter 3 Effects of HIV-1 Tat on oligodendroglial survival and function in vitro 
 
 
(This chapter, in part, was published as a paper in the Journal of Neuroscience in 
August of 2015, 35(32):11384-11398, entitled Oligodendrocytes are targets of HIV-1 
Tat: NMDA and AMPA receptor-mediated effects on survival and development) 
 
Introduction 
As mentioned in earlier chapters, adding adjunctive ‘anti-inflammatory’ agents to 
cART had no significant effect on HAND in HIV+ patients (Tan and McArthur, 2012). 
Since our in vivo studies showed that OLs and myelin were injured in Tat-transgenic 
mice, we hypothesized that Tat may be directly toxic to OLs. To exclude the impacts 
from other cell types, a highly purified OL culture was used to study the direct effects of 
Tat on OLs. 
In vivo OL development is a complex process where migratory and mitotic OPCs 
arise from certain regions of the ventricular zones, move away to different brain regions 
and differentiate into myelinating OLs, which produce myelin to ensheath axons. During 
this process, a series of developmental markers are sequentially expressed, and can be 
used to divide the lineage into distinct phenotypic and biological stages. Early studies 
have shown that the capacity of OL progenitors to differentiate into OLs in vitro is 
identical to those in tissue (Temple and Raff, 1986). In this study, dissociated OL 
cultures were developed from A2B5+ OPCs harvested from 7-8 days old primary
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mixed glia cultures (Knapp et al., 1987; Knapp et al., 2009), and differentiated into OLs 
using specified differentiation medium containing T3 and CNTF. Immature and mature 
OLs were defined as OPCs cultured for 2 days and 7 days in the differentiation medium, 
respectively. At these time points, the majority of the cells are O4+, MBP-/+ in the 
immature OL population, and O4+, MBP+ in the mature OL population.  
OL lineage cells express functional ionotropic glutamate receptors (iGluRs), 
including AMPA-Rs and NMDA-Rs, both in vivo and in vitro (Karadottir et al., 2005; 
Salter and Fern, 2005; Micu et al., 2006; Alix and Fern, 2009). The expression of these 
receptors on OLs is highly heterogeneous. Individual cells express different levels of 
iGluRs, and the distribution, subunit components, and downstream signaling pathways 
of different iGluRs may vary (Karadottir et al., 2005; Matute et al., 2006; Micu et al., 
2006). Adding further complexity, iGluR expression in OLs is also developmentally 
regulated. AMPA-Rs are expressed at all developmental stages, while NMDA-Rs show 
later expression (Salter and Fern, 2005). In addition, the majority of NMDA-Rs 
expressed on OLs are clustered on processes and the myelin sheath while AMPA-Rs 
are evenly distributed on the cell body (Micu et al., 2006). Activation of iGluRs results in 
immature OL death (Deng et al., 2003; Follett et al., 2004) and myelin disruption (Micu 
et al., 2006). Importantly, since OL NMDA-Rs are less susceptible to Mg2+ blockade 
(Karadottir et al., 2005), and OL AMPA-Rs lack the Ca2+-impermeable GluR2 subunit 
(Hollmann and Heinemann, 1994; Matute et al., 2002), the level of extracellular 
glutamate necessary to injure OLs may be much lower than required for excitotoxic 
neuronal injury. 
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Since Tat-induced activation of iGluRs and resulting Ca2+ influx cause neuronal 
injury (King et al., 2006; Kim et al., 2008), we tested whether a similar mechanism exists 
in OLs. Increased [Ca2+]i occurred in immature and mature OLs with Tat treatment, and 
both were attenuated by NMDA-R and AMPA/KA-R antagonists. Additionally, Tat 
caused immature OL death and reduced myelin-like membrane production by mature 
OLs, both in a dose-dependent manner. Both effects were blocked by MK801, while 
CNQX only blocked immature OL death. Since these experiments were performed 
using a highly purified OL culture model, the effects likely reflect direct actions of Tat, 
rather than a response to Tat-induced inflammation. 
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Materials and Methods 
Oligodendroglial cultures 
Primary cultures were prepared from mice (CD-1, Charles River Laboratory, 
Wilmington, MA) of both sexes at postnatal day 0-1 as previously published (Zou et al., 
2011b). In brief, whole brains were dissected and minced before being incubated (37°C, 
5% CO2) with 2.5 mg/ml trypsin (Sigma, St. Louis, MO) and 0.015 mg/ml DNase 
(Sigma) in Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies, Carlsbad, 
CA) for 30 min. Tissue was triturated and re-suspended in DMEM supplemented with 
10% fetal bovine serum (Thermo Scientific Hyclone, Logan, UT), 6 g/l glucose (Sigma), 
sodium bicarbonate, and penicillin/streptomycin (Life Technologies), filtered through 
nylon mesh with pore sizes 100 µm and 40 µm, and then plated in T25 flasks (Corning 
Inc., Corning, NY) pre-coated with poly-L-lysine (1 mg/ml, Sigma) at a density of 2 
brains/flask. 
At day 8, primary glial cultures were put on an orbital shaker (100 rpm, 20 min) to 
dislodge microglia loosely attached to the culture surface. Medium was replaced and 
the flasks were hit sharply against the table 5-10 times to release as many O2A/glial 
progenitor cells as possible. The suspension was panned on a plastic, non-tissue 
culture dish for 2 h to remove adherent astroglia and microglia. Progenitors were plated 
in serum-free medium supplied with 10 ng/ml CNTF (Peprotech, Rocky Hill, NJ), 5 µg/ml 
NAC (Sigma) and 15 nM triiodothyronine (Sigma) on culture surfaces coated with poly-
L-lysine as described above. Medium was changed every 3 d.  
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Viral protein and receptor antagonist treatments 
OL cultures were treated with HIV-1 Tat1-86 (clade B, ImmunoDX LLC, Woburn, 
MA) at 1 nM, 10 nM or 100 nM ± MK801 (20 µM, Tocris Bioscience, Bristol, UK) and 
CNQX (20 µM, Tocris), at day 2 or day 7 after plating the enriched cultures. In selected 
studies, heat-inactivated Tat1-86 was used as a control. If the cells were treated 
concurrently with Tat and MK801 or CNQX, the receptor antagonists were added 30 
min before Tat.  
MK801 and CNQX concentrations were chosen to maximally block the NMDA-R 
and AMPA/KA-R, respectively, as previously reported (Salter and Fern, 2005). 
Nimodipine (10 µM), dantrolene (10 µM), DL-TBOA (100 µM), RS102895 (10 µM), 
SB328437 (10 µM) and the RGDS peptide (10 µM) (all from Tocris Bioscience) were 
used when assessing the effects of different inhibitors on Tat-induced [Ca2+]i change in 
OLs and were added 20 min before Tat treatment and Ca2+ imaging. 
 
Time-lapse analysis of individual OLs 
Enriched immature OLs were plated on a 12-well plate at a density of 1.5 × 104 
cells/well. After Tat ± MK801/CNQX treatment, the plate was transferred to a heating 
insert M12 (Pecon, Erbach, Germany) and put on the scanning stage of a Zeiss Axio 
Observer Z1 microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY) equipped with 
an environmental incubator (Pecon), with a constant temperature (37°C) and CO2 level 
(5%) during the experimental period. Both the heating insert and the environmental 
incubator were pre-warmed to 37°C at least 1 h before the start of the experiment. For 
each treatment, more than 25 OLs were systematically yet arbitrarily chosen, and 
		 34	
repeatedly imaged every hour using an automated stage controlled by the Zeiss 
Axiovision 4.8 software (Carl Zeiss). Viability of the cells was confirmed at the end of 
each experiment using calcein-AM (Life Technologies) staining. Time of cell death was 
determined by carefully assessing all pre-selected OLs in hourly digital images, using 
rigorous morphological criteria, including but not restricted to: (1) loss of phase 
brightness; (2) degenerating processes; and, (3) involution or fragmentation of cell 
soma. Data were analyzed at 4 h intervals and presented as mean percentage of 
survival ± standard error of the mean (SEM) from at least 4 individual experiments (n ≥ 
4; at least 50 cells analyzed per N). Repeated measures ANOVA and post hoc 
Bonferroni’s test were used to compare whether differences between treatments were 
significant (p ≤ 0.05) or not (p > 0.05).  
 
Live-Dead Assay 
Cell viability after Tat treatment was confirmed using the LIVE/DEAD 
Viability/Cytotoxicity Kit (Life Technologies). Twenty microliters of 2 mM ethidium 
homodimer-1 (EthD-1) stock solution and 5 µl of 4 mM calcein- AM stock solution were 
added to 10 ml of sterile, tissue culture–grade D-PBS sequentially and vortexed for 20 
seconds to make the working solution. Five hundred microliters working solution were 
added to each well of a sterile 24-well plate. OLs were plated on 12-mm diameter 
German glass cover slips (Chemglass Life Sciences, Vineland, NJ) and treated with 
vehicle or 100 nM Tat for 24, 48, and 72 h. After treatment, coverslips were quickly 
rinsed in Dulbecco's Phosphate-Buffered Saline once and transferred to individual wells 
of a 24-well plate to incubate in working solution (30 min, room temperature). Coverslips 
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were then carefully inverted onto a clean Superfrost Plus Gold microscope slide (Fisher 
brand) with 10 µl fresh D-PBS and sealed with clear fingernail polish. Fluorescent 
(Ex/Em at ~495/~515 for calcein-AM and Ex/Em ~528/~617 for EthD-1) and phase 
images were taken using a Zeiss Axio Observer Z1 microscope with Zeiss Axiovision 
4.8 software (Carl Zeiss). Live or dead cells were defined by green (calcein-AM) or red 
(EthD-1) fluorescence, respectively. For each n (individual experimental group), 20 
images were systematically, yet arbitrarily taken and analyzed, and the relative ratio of 
live/dead cells was quantified by numbers of green/red fluorescent pixels using ImageJ 
software (National Institutes of Health).  
 
Intracellular calcium assessment 
After 2 or 7 d culture, OLs plated on 35 mm glass-bottom culture dishes (MatTek, 
Ashland, MA) were loaded with 2.5 µM fura-2-AM (Life Technologies) for 30 min at 
37°C. Cells were washed twice and incubated in DMEM for another 30 min to ensure 
de-esterification of the acetoxy methylester (AM) group before transfer to the 
environmental incubator of the Zeiss Axio Observer microscope. Cytosolic [Ca2+]i was 
assessed using the physiology module of the AxioVision software. Fura-2-AM was 
excited at 340 and 380 nm, and emissions collected at 510-540 nm. Data were 
collected every second for the first 90 sec, then every 5 sec for the next minute, then 
every 30 sec for the rest of the 20 min experimental period. The F340/F380 ratio was 
converted to calcium concentration via a standard curve generated using a calcium 
calibration buffer kit (Life Technologies). Data were presented as mean [Ca2+]i ± SEM 
from at least 4 individual experiments (>25 cells analyzed per n).  
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CM-DiI live Staining 
Cells from day 8 primary cultures were plated on 35 mm glass-bottom culture 
dishes (1.5 × 104 cells/dish) and incubated for 6 d in growth medium as described 
above. 2 µg/ml CM-DiI (Life Technologies) was added to the medium, and cells were 
incubated for 5 min before being transferred to 4°C for another 15 min. Cells were 
washed with pre-warmed culture medium, and placed back in the incubator. Treatments 
were applied the next day, prior to placement in the stage incubator. Individual OLs 
were selected as described in the repeated measure paradigm. Fluorescent (Ex at 
560/40, Em at 630/75) and phase images were taken at 0, 24, and 48 h after treatment. 
The membrane area of individual cells, defined as the total red fluorescent area 
surrounding the cell body minus the area of the cell body (Dennis et al., 2008), was 
quantified using IP Lab imaging software (BD Biosciences, Franklin Lakes, NJ).  
 
Immunostaining 
Cells cultured on glass coverslips were fixed with 4% paraformaldehyde and 
permeabilized with Triton-X 100. Neurons, astroglia, microglia, and OLs, were identified 
with antibodies specific to microtubule associated protein 2 (MAP2, 1:1000, Abcam, 
Cambridge, UK), glial fibrillary acidic protein (GFAP, 1:1000, Millipore, Billerica, MA), 
ionized calcium-binding adaptor molecule 1 (Iba-1, 1:500, Wako Chemicals, Richmond, 
VA), and myelin basic protein (MBP, 1:1000, Abcam), and the O4 monoclonal antibody 
(grown in our lab from hybridoma cells (Knapp and Hauser, 1996), 1:20), respectively. 
Antibodies specific to αv or β3 subunits (1:1000, Abcam) were used to identify integrins 
on OLs. Corresponding secondary antibodies were conjugated to Alexa 488 and 594 
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(1:2000, Life Technologies). Cell nuclei were visualized with Hoechst 33342 dye 
(1:2000, Life Technologies); coverslips were mounted with Prolong Gold Antifade 
reagent (Life Technologies). Images were acquired using a Zeiss LSM 700 laser 
scanning confocal microscope and processed using the maximum projection module of 
Zen 2010 software (Carl Zeiss) to show cells in their entirety. 
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Results 
Characterization of OL cultures 
We used dissociated murine OL cultures to study whether the abnormalities of 
OLs and myelin in vivo were a direct effect of Tat, or an indirect effect of Tat-induced 
inflammation. The percentage of cells expressing specific neural and glial cell markers 
was examined in cultures at 2 - 10 d after enrichment. Identification of OLs was made 
by immunostaining with the O4 antibody, which primarily detects the sulfated 
galactolipid sulfatide. In the CNS, sulfatide is expressed only by OLs; it is synthesized 
by immature, proliferating OLs and its expression is maintained in mature cells. As 
shown in Table 1, less than 5% of cells are positive for cell markers other than O4 in 
day 2 and day 5 OL cultures. This ratio increases to 7 - 10% at day 7 and day 10. 
Hence, even after 10 d culture, ≥90% of cells in our culture are OLs. The majority of 
cells that are not O4+ are GFAP+ astrocytes (Table 3.1).  
 
Dose-dependent effect of Tat on viability of immature, but not mature OLs in vitro. 
D2 and D7 OL cultures were treated with Tat or vehicle, and imaged hourly for 72 
h. At D2, almost all OLs showed an immature phenotype, with two or more fine 
processes extending from relatively condensed, ovoid cell bodies. In addition, there are 
no myelin-like membranes extended from processes (Fig. 3.1A-B). Over time, vehicle 
treated cells showed signs of differentiation. The cell body became much larger with 
increased cytoplasmic area (Fig. 3.1A). The maturing OLs developed multiple, thick, 
primary processes from which emanate an extensive network of thinner processes with 
large, myelin-like membrane expansions that are also O4+. Compared to controls, the 
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viability of immature OLs was significantly decreased in a dose-dependent manner after 
treatment with HIV-1 Tat (Fig. 3.1B, D-G). In addition, OLs that survived after 72 h 
lacked the extensive network of branching processes and myelin-like membrane 
extensions that are typical for healthy OLs at this age (Fig. 3.1A). A Live/Dead assay 
confirmed that OLs treated with Tat for 24-72 h exhibited significantly more EthD-1 
staining and less calcein-AM staining than OLs in vehicle-treated groups (Fig. 3.1F-G). 
On the other hand, Tat treatment had no effect on the viability of mature OLs (D7) (Fig. 
3.1C-D).  
 
Myelin-like membranes are reduced by Tat exposure  
Since Tat did not reduce the viability of mature OLs, we examined whether it 
might affect their ability to form myelin-like membranes. Differentiating OLs in vitro 
produce characteristic membranes that are thought to be analogous to myelin 
membranes in the brain, and which contain all major lipids and proteins found in myelin 
within the CNS (Dubois-Dalcq et al., 1986; Knapp et al., 1987; Waggener et al., 2013). 
OL cultures at D7 were labeled with CM-DiI before being treated with vehicle or Tat. 
Randomly selected cells, with the morphology of maturing OLs, were followed using a 
computer-controlled stage for 48 h; phase contrast and fluorescent images were taken 
at 0 h, 24 h and 48 h. Calcein-AM was added to the cultures at the end of the 
experiments to verify cell viability (Fig. 3.2A). Membrane area per OL, as indicated by 
CM-DiI labeling, was calculated using imageJ software as previously published (Dennis 
et al., 2008). In vehicle-treated cultures, individual OLs showed a ~30% increase of 
membrane area at 24 h, suggesting new membrane production in addition to cell 
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growth. This increased membrane size was maintained at 48 h (Fig. 3.2B). 1 nM Tat did 
not have a significant effect on the OL membrane area. However, adding 10 or 100 nM 
Tat to the medium significantly decreased OL membrane area at 24 h (~75% of 0 h), 
and this decreased membrane size was also maintained at 48 h (Fig. 3.2B). 
 
Tat induces Ca2+ influx in both mature and immature OLs in vitro. 
Since Tat has been reported to destabilize Ca2+ signaling in neurons (Kim et al., 
2008; Perry et al., 2010), astroglia (El-Hage et al., 2005) and microglia (Sheng et al., 
2000; Lokensgard et al., 2001), we hypothesized that the above-observed effects of Tat 
on OLs were mediated by changes in OL [Ca2+]i. To test this hypothesis, we first 
investigated whether Tat induces OL [Ca2+]i alterations. Fig. 3.3 shows that Tat caused 
an increase in [Ca2+]i in both D2 and D7 OLs in a dose-dependent manner. The Tat-
induced Ca2+ influx seemed to start from distant regions of processes upon Tat addition 
to the medium (Fig. 3.3B, D). When challenged with 100 nM Tat, [Ca2+]i levels rose to 
~150 nM in D2 OLs and ~230 nM in D7 OLs, and these increased [Ca2+]i levels were 
maintained during a 20 min experimental period (Fig. 3.3B, D-F). The Tat-induced 
[Ca2+]i increase was dose dependent; with a lower Tat (1 nM) exposure, [Ca2+]i returned 
to the control level after 5 min (Fig. 3.3E-F, cyan line). Furthermore, the Tat-induced 
[Ca2+]i increase was completely abolished in Ca2+-free medium (Fig. 3.3E-F, blue line) 
and greatly attenuated when Tat was heat-inactivated (Fig. 3.3E-F, black line).   
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Blocking iGluRs attenuates the Tat-induced [Ca2+]i increase 
Interactions between Tat and iGluRs lead to iGluR activation and Ca2+ influx, 
which have been reported extensively in neurons (Haughey et al., 2001; Kim et al., 
2008). We therefore examined whether the Tat-induced Ca2+ influx in OLs is also 
mediated by iGluRs. Since iGluR expression and subunit composition is 
developmentally regulated and highly heterogeneous (Gallo and Ghiani, 2000; Itoh et 
al., 2002; Cavaliere et al., 2012) in OLs, we first verified the expression of functional 
iGluRs on our cultured OLs. In immature, D2 OLs, NMDA at both 50 µM and 300 µM 
induced a minimum Ca2+ response (Fig. 3.4A, cyan and blue lines), while either 50 µM 
or 300 µM AMPA induced a significant Ca2+ influx lasting over 20 min (Fig. 3.4A, yellow 
and brown lines). These results are consistent with the fact that the majority of the 
iGluRs expressed on immature OL somas are AMPA/KA receptors (Gallo and Ghiani, 
2000; Itoh et al., 2002). In mature OLs, 50 µM NMDA invoked a small Ca2+ response 
(~60 nM) that was significantly above the control level (~40 nM) (Fig. 3.4B, cyan line vs. 
white line). A higher NMDA exposure (300 µM) elicited a sharp increase of [Ca2+]i to a 
level similar to that induced by Tat (Fig. 3.4B blue line, vs. Fig. 3.3F red line). This high 
[Ca2+]i level came down to ~60 nM within 10 min, but remained significantly higher than 
in vehicle-treated OLs. The AMPA responses of mature OLs were somewhat different. 
50 µM AMPA caused a moderate [Ca2+]i increase in mature OLs that recovered within 
10 min (Fig. 3.4B, yellow line). 300 µM AMPA induced an initial [Ca2+]i increase to ~110 
nM, which then rose consistently over the 20 min experimental period (Fig. 3.4B, brown 
line).  
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We next examined whether blocking iGluRs affected Tat-induced [Ca2+]i changes 
in OLs. In immature OLs, the [Ca2+]i increase induced by 10 nM Tat was completely 
blocked by both MK801 and CNQX (Fig. 3.4C and E, yellow line), but [Ca2+]i increases 
induced by 100 nM Tat were only reduced to ~100 nM (Fig. 3.4C and E, brown line). 
MK801 and CNQX additively inhibited the effect of 100 nM Tat, but could not completely 
block the [Ca2+]i increase (Fig. 3.4G, brown line). The response in mature OLs was 
different. With 10 nM Tat, the initial [Ca2+]i level was significantly attenuated by MK801 
or CNQX, and the [Ca2+]i level gradually returned to control over 5 min (Fig. 3.4D and F, 
yellow line). When MK801 and CNQX were added together, the effect of 10 nM Tat was 
completely blocked (Fig. 3.4H, yellow line). In contrast, only MK801 attenuated the initial 
[Ca2+]i rise caused by 100 nM Tat, which was reduced to ~ 90 nM and maintained at this 
level over the 20 min experimental period. With CNQX, [Ca2+]i levels were reduced only 
at later time points (Fig. 3.4D&F, brown line). MK801 and CNQX together had no 
additive effect on 100 nM Tat-induced [Ca2+]i change in mature OLs (Fig. 3.4H, brown 
line). These results indicate that Tat-induced [Ca2+]i changes in OLs were mediated by 
both NMDA-R and AMPA/KA-R activation. Further, since iGluR antagonists (20 µM) did 
not completely block [Ca2+]i changes induced by the higher Tat concentration (100 nM), 
Tat may activate iGluRs in a way that cannot be completely inhibited by MK801/CNQX, 
or Tat may interact with other molecules on the surface of OLs that mediate [Ca2+]i 
change. 
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Blocking alternative, non-iGluR targets has no effect on Tat-induced increases in [Ca2+]i 
Since Tat-induced [Ca2+]i  increases were not completely blocked by inhibiting 
iGluRs, we tested a series of alternative Ca2+ modulators. The Tat-induced OL [Ca2+]i 
increase was abolished in Ca2+-free medium (Fig. 3.5 E-F). To test whether the initial 
Ca2+ influx triggers Ca2+-induced-Ca2+ release from internal stores, immature/mature 
OLs were treated with 10 µM dantrolene for 20 min before addition of Tat, but this had 
no effect on Tat-induced [Ca2+]i change in OLs. OLs express abundant αvβ3 integrin 
(Fig. 3.5B), which has been reported to interact with Tat (Urbinati et al., 2005b; Urbinati 
et al., 2012). However, blocking integrin with the RGDS inhibitor peptide had no effect 
on Tat-induced [Ca2+]i increase in immature or mature OLs (Fig. 3.5A). Similarly, the L-
type voltage-gated calcium channel blocker nimodipine (10 µM), CCR2 receptor 
inhibitor RS102895 (10 µM), CCR3 receptor inhibitor SB328437 (10 µM) and sodium-
dependent Glutamate transporter inhibitor DL-TBOA (100 µM) all had no effect on Tat-
induced [Ca2+]i changes in either immature or mature OLs (Fig. 3.5A).  
 
CNQX and MK801 effects on OL survival and membrane production 
Since Tat-induced [Ca2+]i changes were attenuated by MK801 and/or CNQX, we 
examined whether blocking iGluRs would also reverse Tat effects on immature OL 
survival. Both CNQX and MK801 (20 µM) completely reversed the effect of Tat on OL 
viability at 24, 48, and 72 h. CNQX by itself had no effect on OL viability, while cells 
treated with MK801 alone had a significantly higher survival rate than control (Fig. 
3.6A). We next tested whether blocking iGluRs could also reverse the effect of Tat on 
the area of myelin-like membranes produced by mature OLs. Neither CNQX or MK801 
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by themselves had any effect on the area of myelin-like membranes produced by 
mature OLs at either 24 or 48 h. Exposure to 100 nM Tat significantly decreased the 
size of the membrane area by >20% after 24 h. This effect was completely reversed by 
MK801, but not by CNQX.  Results at 48 h were similar (Fig. 3.6B). 
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Discussion 
Our findings through these studies establish that HIV-1 Tat, through activation of 
iGluRs, increases [Ca2+]i in OLs. In highly purified murine OL cultures, the outcome of 
Tat exposure varies with the stage of differentiation. At the level in which Tat reduced 
immature OL survival, mature OLs remain viable despite persistent elevations in [Ca2+]i, 
but have reduced myelin-like membrane areas. Blocking either NMDA-Rs or AMPA-
/KA-Rs by MK801 or CNQX, respectively, completely reversed Tat-induced immature 
OLs death, but only MK801 reverses Tat-induced membrane area reduction in mature 
OLs. These results suggest that both NMDA-Rs and AMPA/KA-Rs participates in Tat-
induced immature OLs death, but only NMDA-Rs played a role in mature OLs 
membrane production. 
 
Tat dosage 
Tat is a highly conserved viral protein, essential for viral replication and efficient 
transcription of viral genes, which can be found in blood (Ensoli et al., 1993), 
extracellular matrix (Urbinati et al., 2005a), and cerebrospinal fluid (Tardieu et al., 
1992). Importantly, Tat is produced by infected cells despite cART (Johnson et al., 
2013). Levels of soluble Tat in the sera of HIV-1-infected individuals are within the 
range of 2 – 40 ng/ml (Xiao et al., 2000). Tat has a high affinity for cell surface proteins 
such as heparin sulfate proteoglycan (Liu et al., 2000) and extracellular cellular matrix 
components such as glycosaminoglycans (Xiao et al., 2000). Microdomains near 
productively-infected cells may have even higher levels. Thus, brain cells may be 
exposed to higher levels of Tat than what is measured in blood. It has also been 
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reported that the potency of recombinant Tat, as used in our experiments, is much less 
than Tat secreted by infected cells (Li et al., 2008). Hence, the concentrations of Tat 
used in our experiments (1-100 nM), are a reasonable approximation of titers in HIV-
infected brains.  
 
Tat-induced [Ca2+]i increase 
Tat disrupts Ca2+ homeostasis in astroglia (El-Hage et al., 2005; El-Hage et al., 
2008b), microglia (Sheng et al., 2000; Lokensgard et al., 2001), macrophages 
(Contreras et al., 2005), and neurons (Haughey and Mattson, 2002; Zhu et al., 2009). 
We found that Tat induced a concentration-dependent [Ca2+]i increase in both immature 
and mature OLs. The primary source of Ca2+ was extracellular, since the [Ca2+]i 
increases were abolished in Ca2+-free medium. Transient [Ca2+]i increases occurred at 1 
nM Tat with more sustained [Ca2+]i elevations at 10-100 nM Tat. Higher Tat 
concentrations (≥10 nM) may elicit an initial [Ca2+]i increase that depolarizes the 
membrane, leading to secondary Ca2+ influx via voltage-gated calcium channels. Such 
channels are expressed by OLs and activated by the cation influx via glycine receptors 
and Na+-dependent transporters (Kirischuk et al., 1995; Belachew et al., 2000). 
Alternatively, the [Ca2+]i increase induced by 1 nM Tat may be below the threshold 
required to activate Ca2+-induced Ca2+ release from internal Ca2+ stores. Neither the L-
type voltage-gated calcium channel blocker nimodipine nor the ryanodine receptor 
inhibitor dantrolene affected Tat-induced [Ca2+]i increases (Fig. 3.5A), indicating the 
involvement of alternative molecular targets (see below). Notably, 1 nM Tat does not 
affect immature OL viability or mature OL membrane area. These results strongly 
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suggest the existence of a [Ca2+]i threshold above which downstream signaling 
molecules involved in functional effects, such as CaMKIIβ, will be activated. 
 
iGluRs expression on OLs 
We found that stage of development was a significant determinant in the OL 
response to Tat, possibly due to developmentally-regulated expression of iGluRs on 
OLs (Deng et al., 2003). In OL cultures, AMPA elicited a dose-dependent [Ca2+]i 
increase in immature OLs, while even high NMDA concentrations elevated [Ca2+]i 
minimally (Fig. 3.4A). Mature OLs responded to both AMPA and NMDA with prominent 
[Ca2+]i increases. These results are consistent with earlier studies showing that NMDA-
evoked currents were detected in precursor, immature and mature OLs isolated from 
murine cerebellum and corpus callosum (Karadottir et al., 2005; Salter and Fern, 2005). 
A more recent study by Alix and Fern (2009) also demonstrated the co-localization of 
NMDA receptor NR1 subunit and CNPase+ oligodendroglial processes in P10 rat optic 
nerve. At odds with these reports, De Biase et al., (2010) assessed gene expression in 
acutely purified/sorted CNS cells (Cahoy et al., 2008) and concluded that levels of 
NMDA-Rs and AMPA-Rs are high in NG2+ OL progenitors, but decline markedly with 
maturation. Different receptor levels might reflect the effect of isolation procedures, 
although this has not been explored.  
NMDA-Rs on myelinating OLs in vivo were found clustered in processes and on 
myelin (Salter and Fern, 2005; Micu et al., 2006). Consistent with this localization, the 
[Ca2+]i increases mediated by Tat-NDMA-Rs interactions began at distal processes and 
traveled proximally (Fig. 3.3). De Biase et al., (2010) released caged glutamate by UV 
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photolysis in a 100-µm circle centered on the cell body, and only detected slight NMDA 
currents. Glutamate released in this way may be sequestered by neighboring cells prior 
to stimulating NMDA-Rs on more distal OL processes. It is noteworthy that Ca2+ 
responses to AMPA in immature OLs are more homogeneous than in mature OLs, 
suggesting a higher variability of AMPA-R expression or a greater diversity in the 
composition of AMPA-R subunits with maturation, as seen in vivo (Matute et al., 2002; 
Williams et al., 2009).  
 
iGluRs mediate Tat-Induced [Ca2+]i increase 
It is not surprising that Tat interacts with NMDA-Rs in OLs, since Tat-NMDA-R 
interactions occur in neurons (King et al., 2006; Kim et al., 2008; Rumbaugh et al., 
2012; Capone et al., 2013). However, since NMDA minimally affected [Ca2+]i in 
immature OLs, it was intriguing that Tat-induced [Ca2+]i increases were attenuated by 
MK801. Tat and NMDA appear to interact differently with NMDA-Rs, since Tat-NMDA-R 
interactions cause persistent, rather than transient, [Ca2+]i  increases (Fig. 3.4 and 
(Fitting et al., 2014)). CNQX also attenuated the effects of Tat on [Ca2+]i, which was 
unexpected since direct Tat-AMPA/KA-Rs interactions have never been reported. In 
neurons, activation of cytoplasmic CaMKII recruits AMPA-Rs from intracellular vesicles 
to cytoplasmic membranes, and increases the likelihood of channel opening by 
phosphorylating Ser-831 of AMPA-R GluA1 subunits (Milstein and Nicoll, 2008; 
Derkach, 2011; Kristensen et al., 2011). We found that exposure to Tat leads to 
phosphorylation and activation of CaMKIIβ in OLs (see Chapter 5). Since the 
expression of the major cytoplasmic Ca2+ binding protein calbindin is extremely low 
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compared to other CNS cells, (Baimbridge et al., 1992; Zhang et al., 2014), we propose 
that Tat-NMDA-R interactions lead to an initial Ca2+ influx that activates CaMKIIβ, which 
then recruits and phosphorylates AMPA-Rs and raises [Ca2+]i levels. Combined MK801 
and CNQX had no additive effect, implicating additional, non-iGluR cellular components 
in Ca2+ responses to Tat. Blocking experiments preclude a role for integrins, chemokine 
receptors CCR3 and CCR2, sodium-dependent glutamate transporters, and ryanodine 
receptors in Tat-induced [Ca2+]i increases (Fig. 3.5). Similar to neurons (Fitting et al., 
2014), Tat-activated NMDA-Rs might cause Na+ influx, reversing Na+/Ca2+ exchange 
and triggering mitochondrial Ca2+ release.  
  
Effects of Tat on OL viability and function 
Ca2+ influx via AMPA/KA-Rs can activate various death pathways in OLs 
(Matute, 2011). AMPA-R activation leads to caspase-8 recruitment and Bid truncation, 
while KA-R activation has been linked to caspase-3 and caspase-9 activation (Sanchez-
Gomez et al., 2003; Matute et al., 2006). We found that CNQX completely reversed Tat-
induced death of immature OLs, implicating activation of AMPA/KA-R-mediated death 
pathways. Surprisingly, MK801 had a similar effect, suggesting a requirement for both 
NMDA-Rs and AMPA/KA-Rs. This further implicates NMDA-R-mediated AMPA/KA-R 
activation. Interestingly, MK801 increased baseline survival of immature OLs, 
suggesting that some glutamate is released from OLs injured during the culture 
process.  
Mature OLs remained viable when exposed to Tat, even when [Ca2+]i was 
elevated to a level that resulted in immature OLs death. This is consistent with previous 
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findings that Ca2+-dependent excitotoxicity decreases with OL maturation (McDonald et 
al., 1998; Kavanaugh et al., 2000; Itoh et al., 2002; Deng et al., 2003). Rumbaugh et al. 
(2013)  have proposed that the peptide Tat31-61 directly binds the NR1 subunit resulting 
in NMDA-R activation. In vivo, NMDA-Rs are mainly clustered on cytoplasmic 
processes and the myelin sheath, and their activation causes process degeneration and 
myelin injury (Micu et al., 2006). Consistent with this subcellular distribution of NMDA-
Rs, our experiments showed that Tat-induced [Ca2+]i increases in mature OLs originate 
at the distal processes and/or the peripheral edge of the myelin-like membranes (Fig. 
3.3D). Importantly, the resultant reduction in myelin-like membranes can be reversed by 
MK801, but not CNQX (Fig. 3.6), suggesting that membrane retraction/OL injury is 
mediated by a common mechanism involving NMDA-R activation and Ca2+ influx. It is 
possible that Ca2+ influx due to Tat-NMDA-R interactions will generate a highly localized 
increase in [Ca2+]i within distal processes/myelin membranes that leads to local 
CaMKIIβ activation (See Chapter 5). Waggener et al. (2013) showed that CaMKIIβ 
regulates OL maturation and CNS myelination via stabilizing the actin cytoskeleton. Our 
findings suggest that CaMKIIβ activation by Tat may also underlie some myelin damage 
with HIV infection.  
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Table 3.1. Percentage of cells expressing neuron/glial specific markers at various 
times in vitro 
 
 O4+ GFAP+ MAP2+ Iba+ 
Day 2  
(n=4, 372 cells) 
98.76 ± 0.73% 1.00 ± 0.58% 0% 0.24 ± 0.24% 
Day 5 
(n=4, 413 cells) 
96.35 ± 0.49% 3.15 ± 0.62% 0% 0.50 ± 0.29% 
Day 7 
(n=4, 396 cells) 
93.18 ± 0.15% 5.35 ± 0.61% 0.25 ± 0.25% 1.22 ± 0.46% 
Day 10 
(n=4, 383 cells) 
90.60 ± 0.39% 7.31 ± 0.37% 0% 2.10 ± 0.44% 
 
n: number of individual cultures. 
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Figure 3.1
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Figure 3.1. Survival of Tat-treated OLs. (A-C) Sample images of OL cultures treated 
with vehicle or Tat (100 nM) after 0, 24, 48 and 72 h. (A) Immature OLs treated with 
vehicle grow normally and differentiate over the 72 h period. At the end of 72 h, cells 
have complex process networks with myelin-like membranes. (Scale bar: 100 µm for A-
C) (B) Immature OLs treated with 100 nM Tat. Both OLs in the field were healthy at 0 h. 
One OL was dead after 72 h (white arrow). Although the other OL survived, its process 
network was greatly reduced. An astrocyte at the lower right corner migrated out of the 
field by 24 h. (C) A mature OL treated with 100 nM Tat appeared healthy and still 
maintained a complex process network after 72 h, even though it underwent extensive 
process reorganization. The double arrow marks a major process that was retracted. 
(D) OL vulnerability to Tat was dependent on differentiation. Almost all mature OLs 
(>95%) survived for the 72 h experimental period, whether they were treated with 
vehicle or 100 nM Tat. In contrast, survival of immature OLs was significantly reduced 
by 100 nM Tat, even at 24 h. (*p<0.05 vs. immature OL controls; one-way ANOVA 
followed by post-hoc Bonferroni’s test; n=4 individual experiments; at least 25 cells were 
counted for each n) (E) The dose-dependent effect of Tat on immature OL survival. 
Immature OLs at day 2 were treated with 1, 10 and 100 nM Tat for 24, 48 and 72 h. 1 
nM Tat shows no obvious effect on OL survival, while 10 nM Tat reduces survival by 10 
– 15% when compared to controls at 24, 48 and 72h. The cytotoxic effect of 100 nM Tat 
is even more significant (22 – 35% reduction in survival). (*p<0.05 vs. control; #p<0.05 
vs. 10 nM Tat group; two-way ANOVA followed by post-hoc Bonferroni’s test; n=4 
individual experiments; >40 cells were counted for each n.) (F-G) The Live-Dead assay 
shows that 100 nM Tat significantly increased immature OL death at 24, 48 and 72 h. 
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(F) Corresponding phase and fluorescent images of calcein-AM (live cells, green) and 
EthD-1 (dead cells, red) labeled of D2 immature OLs treated with vehicle or 100 nM Tat 
for 72 h. A majority of cultured cells appeared to shift from green to red with Tat 
treatment. (G) At all time points, 100 nM Tat significantly increased the proportion of red 
pixels and reduced numbers of green pixels, indicating less OL survival with Tat and 
validating the visual observation in F. (*p<0.05 number of red pixels; Tat vs. control of 
same time point; #p<0.05, number of green pixels; Tat vs. control of same time point; 
one-way ANOVA followed by post-hoc Bonferroni’s test; n=4 individual experiments; 20 
randomly selected images were analyzed for each n.) 
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Figure 3.2 
 
 
Figure 3.2. Tat reduces myelin-like membranes of mature OLs. (A). Sample images 
showing changes in mature OL membrane area over 48 h. Cells were labeled with 2 
µg/ml CM-DiI 1 d before Tat treatment. Phase contrast and fluorescent images of the 
same cell were taken at 0, 24, and 48 h. Phase and fluorescent images were merged to 
better visualize the myelin-like membrane structures. At the end of the experimental 
period, cells were labeled with calcein-AM to verify viability (green ifluorescence). The 
yellow arrowhead indicates an area with an obvious reduction in the area of the cellular 
processes (loss of red fluorescence) over time. (B) Quantification of the change in 
membrane area in vehicle and Tat-treated OLs. At both 24 h and 48 h, vehicle-treated 
OLs showed ~25% growth of membrane area. 1 nM Tat did not have any significant 
effect on the membrane area when compared with controls. However, 10 or 100 nM 
Tat-treated OLs at 24 h and 48 h exhibited ~20% reductions in membrane area 
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compared to 0 h (* p<0.05, two-way ANOVA followed by post-hoc Bonferroni’s test; n=4 
individual experiments; at least 25 cells were counted for each n).  
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Figure 3.3 
 
 
Figure 3.3. Tat induces Ca2+ influx in mature and immature OLs. (A-D) Sample 
images showing changes of intracellular Ca2+ concentration over a 20-min period in 
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immature (A-B) and mature (C-D) OLs treated with vehicle (A & C) or 100 nM Tat (B & 
D). [Ca2+]i was assessed by fura-2 AM 340/380 fluorescence ratio and was displayed as 
pseudocolored images generated by Zeiss AxioVision 4.8 software. (E-F) Tat induces 
dose-dependent [Ca2+]i increases in both immature (E) and mature (F) OLs. This effect 
is completely abolished in Ca2+-free medium, and greatly attenuated by heat inactivation 
of Tat. (Vertical dashed line indicates the time point (30 s) when treatment was added 
*p<0.05 vs. control; #p<0.05, vs. 100 nM Tat; two-way ANOVA followed by post-hoc 
Bonferroni’s test; n=4 individual experiments; at least 7 cells were counted for each n. 
Scale Bar: 50 µm). 
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Figure 3.4 
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Figure 3.4. Tat-induced [Ca2+]i increases in OLs are partially reversed by iGluR 
antagonists. (A-B): Expression of functional NMDA-R and AMPA-Rs on OLs. (A) In 
immature OLs, AMPA (at both 50 and 300 µM) causes [Ca2+]i increases while NMDA 
responses are minimal. (B) In mature OLs, NMDA leads to a dose-dependent [Ca2+]i 
increase. AMPA elicits a [Ca2+]i increase only at the higher 300 µM concentration, and 
variability between cells is quite high. (C-H) iGluR antagonists attenuate Tat-induced 
[Ca2+]i increases in OLs. (C, E, G) In immature OLs, MK801 and/or CNQX completely 
blocks the [Ca2+]i increase induced by 10 nM Tat but only partially inhibits the [Ca2+]i 
increase elicited by 100 nM Tat. (D, F, H). In mature OLs, the 10 nM Tat-induced [Ca2+]i 
increase is similarly abolished by MK801 and/or CNQX. In contrast, the [Ca2+]i increase 
induced by 100 nM Tat is only partially blocked by MK801 and/or CNQX (*p<0.05 vs. 
Control; #p<0.05 vs. 100 nM Tat; two-way ANOVA followed by post-hoc Bonferroni’s 
test; n=4 individual experiments; at least 7 cells were counted for each n). 
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Figure 3.5 
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Figure 3.5. Blocking alternative, non-iGluR targets has no effect on Tat-induced 
increases in [Ca2+]i. A. Immature or mature OLs were exposed to nimodipine (L-type 
voltage-gated calcium channel inhibitor, 10 µM), dantrolene (ryanodine receptor 
inhibitor, 10 µM), DL-TBOA (sodium-dependent glutamate transporter inhibitor, 100 
µM), RS102895 (CCR2 inhibitor, 10 µM), SB328437 (CCR3 inhibitor 10 µM), or the 
RGDS peptide (integrin inhibitor, 10 µM) for 20 min prior to Tat treatment. None of these 
inhibitors affected Tat-induced OL [Ca2+]i increases. (*p<0.05 vs. control; two-way 
ANOVA followed by post-hoc Bonferroni’s test; n=3 individual experiments; at least 7 
cells were counted for each n). B. Expression of αV and β3 integrin on O4+ and MBP+ 
OLs (Scale bar: 50 µm). 
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Figure 3.6 
 
 
Figure 3.6. Effects of iGluR antagonists on Tat-induced functional effects. (A) 
Immature OLs treated with 100 nM Tat exhibit a significantly reduced survival rate at all 
time points, compared to control. Either 20 µM CNQX or 20 µM MK801 completely 
reversed the Tat-induced cell death at all time points. 20 µM CNQX by itself did not 
change the viability of immature OLs. On the other hand, at both 48 and 72 h, 20 µM 
MK801 significantly increased the viability of OLs (*p<0.05, less survival vs. control; 
#p<0.05, greater survival vs. control; one-way ANOVA followed by post-hoc Bonferroni’s 
test; n=4 individual experiments; at least 25 cells were counted for each n). (B) At both 
24 h and 48 h, mature OLs treated with 100 nM Tat exhibit a significant, ~20% reduction 
in total membrane area when compared to 0 h. In contrast, the membrane area of 
vehicle-treated OLs increased significantly by ~25% at both time points. 20 µM MK801, 
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but not CNQX, reversed the reduction in membrane area caused by Tat. Neither MK801 
nor CNQX by itself had any effect on OL membrane production (*p<0.05 vs. 0 h; one-
way ANOVA followed by post-hoc Bonferroni’s test. n=4 individual experiments; at least 
25 cells were counted for each n). 
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Chapter 4 Tat affects mature OL membrane change via CaMKIIβ activation 
 
 
(This chapter, in part, was published as a paper in the Journal of Neuroscience in 
August of 2015, 35(32):11384-11398, entitled Oligodendrocytes are targets of HIV-1 
Tat: NMDA and AMPA receptor-mediated effects on survival and development) 
 
Introduction 
It is interesting that mature OLs exposed to HIV-1 Tat exhibit no changes of 
viability, but local degeneration of processes and membranes, which leads to an overall 
reduction of myelin-like membrane area. We further investigated the pathways involved 
in mature OL membrane change, and focused on molecules involved in Ca2+ signaling 
and cytoskeleton changes. 
CaM is the major intracellular receptor for Ca2+. Studies by Faas et al., (2011)  
showed that Ca2+ binds more rapidly to CaM than to other Ca2+-binding proteins. 
Besides, the expression of the major cytoplasmic Ca2+ binding protein calbindin is 
extremely low compared to other CNS cells, (Baimbridge et al., 1992; Zhang et al., 
2014). Hence, CaM may be the major determinant of [Ca2+]i after iGluRs-mediated Ca2+ 
influx. Ca2+/CaM binds and activates Ca2+/CaM-dependent protein Kinase II (CaMKII), 
which is central to the coordination of Ca2+ signal transduction. The predominant 
isoform of CaMKII in OLs, CaMKIIβ, has been repeatedly reported to be involved in
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actin cytoskeleton re-organization (O'Leary et al., 2006; Okamoto et al., 2007; Lin and 
Redmond, 2008; Okamoto et al., 2009), and thus has the potential to be the mediator of 
Tat-induced membrane reduction in mature OLs. 
The holoenzyme of CaMKII has been proposed to be a dodecameric structure 
composed of 12 monomers that form two stacked hexagonal rings (Kolodziej et al., 
2000). Each CaMKII monomer contains four functional domains, a kinase catalytic 
domain, an autoinhibitory (regulatory) domain, an association (oligomerization) domain 
and a central variable domain that is subject to alternative splicing (Hudmon and 
Schulman, 2002a). The family of CaMKII isoforms is encoded by 4 closely related 
genes (α, β, γ, δ), among which CaMKIIβ is the major isoform expressed in murine OLs 
(Waggener et al., 2013) and has morphogenic functions not shared by other isoforms 
(O'Leary et al., 2006). The v1 variable domain of CaMKIIβ, which located C-term to the 
Ca2+/CaM binding domain, has been shown to bundle F-actin under resting state 
(Meyer et al., 1992; O'Leary et al., 2006; Okamoto et al., 2007) and stabilize 
cytoskeleton structure. Ca2+/CaM binding induces a conformational change in CaMKIIβ, 
which activates its kinase activity. More importantly, this conformational change also 
exposes a critical phosphorylation site (T287) on CaMKIIβ, which can be 
autophosphorylated by activated neighboring subunits in the same holoenzyme 
(Hudmon and Schulman, 2002a). T287 autophosphorylation not only increases the 
affinity between CaMKIIβ and Ca2+/CaM by ~1000 fold (Meyer et al., 1992), but also 
induces generation of autonomous activity in CaMKIIβ, which phosphorylates its 
neighboring CaMKIIβ subunits on multiple sites, including T306/307 in the variable 
domain. It has been reported that binding of Ca2+/CaM and autophosphorylation on 
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T306/307 result in dissociation of CaMKIIβ from F-actin, followed by cytoskeleton 
collapse in hippocampal neurons (Okamoto et al., 2007; Okamoto et al., 2009).  
Activation of CaMKII by NMDA-Rs is an important step in long-term potentiation 
of synaptic transmission in hippocampal neurons (Malenka and Nicoll, 1999). NMDA-R-
mediated Ca2+ influx activates CaMKII, which promotes synaptic insertion and single 
channel conduction of AMPA-Rs (Rongo and Kaplan, 1999; Hayashi et al., 2000). 
Studies by Bayer et al., (2001)  further shown that interactions between NR2B subunit 
of NMDA-Rs can induce synaptic translocation of CaMKII, which facilitates its activation 
by NMDA-Rs-mediated Ca2+ influx. It is also noteworthy that the interaction between 
NR2B and CaMKII generates a Ca2+/CaM-independent autonomous activity that is 
similar to CaMKII T287 autophosphorylation, and thus possessing the potential of 
T306/T307 phosphorylation. In addition, a recent study also showed that 
pharmacologically inhibiting CaMKIIβ activation in vitro restrains the morphological 
maturation of differentiating rat OLs, while systemic knock-out of CaMKIIβ in vivo leads 
to an increase in the g-ratio (decrease in thickness) of the myelin sheath (Waggener et 
al., 2013), suggesting that CaMKIIβ plays an important role in OL differentiation and 
function. Results from our previous work indicated that Tat induces a persistent [Ca2+]i 
increase via NMDA-Rs and AMPA/KA-Rs activation. We thus hypothesized that the 
[Ca2+]i increase in mature OLs activates CaMKIIβ and leads to membrane collapse. Our 
results showed that CaMKIIβ activation, which is assessed by the level of T287 
phosphorylation, was significantly increased in Tat-treated OLs. The Tat-induced 
CaMKIIβ activation can be completely blocked by MK801, coincident with our previous 
experimental results that MK801 completely reversed the Tat-induced myelin-like 
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membrane reduction in mature OLs (chapter 3). CNQX only partially reverse the Tat-
induced CaMKIIβ activation, suggesting that Ca2+ influx via AMPA/KA-Rs also activates 
CaMKIIβ, but to a less extent.  
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Materials and Methods: 
Western blotting of CaMKIIβ and T-287 phosphorylated CaMKIIβ 
Western blotting was performed as described previously (Chapter 3). In short, 
Proteins were extracted from cultured OLs or brain tissues using RIPA buffer with 
protease and phosphatase inhibitors. The concentration of extracted proteins was 
assessed using the BCA assay. Target proteins were probed with primary antibodies for 
CaMKIIβ (1:1000, Life Technologies) and phosphor-CaMKIIβ (T287) (1:1000, Abcam) at 
4°C overnight. Membranes were incubated with appropriate IRDye secondary 
antibodies (1:3000, Li-COR, Lincoln, NE) for 1 h at room temperature, and imaged 
using an Odyssey Imager (Li-COR). Protein bands were quantified using Li-COR image 
studio software.  
 
RT-PCR analysis of CaMKII transcription 
RNAs were extracted from OLs or cerebral cortex of P2 ICR mice using the 
miRNAeasy Mini Kit (QIAGEN Inc. Valencia, CA). Concentration of RNAs of each 
sample was determined using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific). Equal amounts of RNAs were then used as templates to transcribe cDNA 
using a high capacity cDNA reverse transcription kit (Life Technologies).   
Gene-specific primer pairs were designed using the NCBI Gene database and 
primer-design web tool (http://www.ncbi.nlm.nih.gov). The web tool generates an array 
of primer sets that fit the parameters defined by users. These parameters include size of 
the final product and the primers, whether primers span the junctions between exons, 
GC contents of the primer etc. For each isoform of CaMKII, two primer sets with the 
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least GC contents at the 3’-terminus were picked and tested using SensiMi SYBR Hi-
ROX Kit (Bioline USA Corp, Taunton MA) on a Roche Lightcycler 96 real-time PCR 
system (Roche Diagnostics Corporation, Indianapolis, IN). First, a test run using a range 
of Tm (56 – 66°C) were performed to determine the optimal Tm for all the primer sets. 
Efficiency of all primer sets was then decided by running RT-PCR with Tm set at the 
optimal temperature (60°C) and a series of dilution (1:2.5 – 1:20) of transcribed cDNA. 
For each isoform of CaMKII, the primer set with better efficiency was chosen to be used 
in determining the expression of CaMKII in cultured OLs. The sequences of these 
primer sets are listed below: 
CaMKIIα:  
Primer pair 2 (Efficiency = 1.98) 
Forward Primer:  5’-AGACACCAAAGTGCGCAAAC-3’ 
Reverse primer: 5’-TTCCAGGGTCGCACATCTTC-3’ 
CaMKIIβ 
Primer Pair 3 (Efficiency = 1.92) 
Forward primer 5’-GGTTTGGATTTGCGGGAACG-3’ 
Reverse primer 5’-ACAGGATCACCCCACATGCC-3’ 
CaMKIIγ 
Primer pair 2 (Efficiency = 1.98) 
Forward Primer:  5’-CACCGACGACTACCAGCTTT-3’ 
Reverse primer: 5’-TTTCTGATGATCTCGGGCGG-3’ 
CaMKIIδ 
Primer pair 1 (Efficiency = 2.00) 
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Forward Primer:  5’-TCGGAGGAGGGCTTCCATTA-3’ 
Reverse primer: 5’-TCTCAGGCTTTAGGTCCCGA-3’ 
 
siRNA and antisense oligonucleotide sequence that targets mRNA of CaMKIIβ 
 ON-TARGETplus SMARTpool siRNA against mice Camk2b were commercially 
available from Thermo Fisher Scientifc/Dharmacon Inc., Lafayette, CO. The 
SMARTpool siRNA contains siRNAs specific to 4 different sequences in the Camk2b 
gene. These sequences are listed as below: 
siRNA 1 (J-062002-05): target sequence: 5’-GCACGUCAUUGGCGAGGAU-3’ 
siRNA 2 (J-062002-06): target sequence: 5’-GAAGGAGGCCUACGGCAAA-3’ 
siRNA 3 (J-062002-07): target sequence: 5’-CCAAGAUCAUUAAUACCAA-3’ 
siRNA 4 (J-062002-08): target sequence: 5’-CCAUGGGUCUGCCAACGUU-3’ 
Mice CaMKIIβ mRNA sequence was acquired from the NCBI Gene Database 
(NCBI Reference Sequence#: NM_001174053.1). The antisense oligonucleotide 
sequence was designed by Integrated DNA Technologies (IDT) AntiSense Design tool 
(http://www.idtdna.com/Scitools/Applications/AntiSense/Antisense.aspx?source=menu). 
The tool generates a maximum of 20 antisense nucleotides sequences at one time, 
among which three antisense oligonucleotide sequences (Sequence 1, 14 and 15) 
targeting different, non-overlapping regions were picked and tested. Their sequences 
are listed as below: 
Sequence 1:  5’-ACCTCCATACCTCACTCCC-3’ 
Sequence 14: 5’-GCCACTCAGATGTTTACCCT-3' 
Sequence 15: 5'-GCTTGTGTTGGTCCTCATCCC-3' 
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All sequences ordered are phosphorothioate-modified to be nuclease-resistant. 
 
Antisense oligonucleotide sequence delivery 
To inhibit expression of CaMKIIβ, several methods have been used to deliver the 
antisense oligonucleotide sequence or ON-TARGETplus SMARTpool siRNA to mature 
OLs. 
1. Direct feed: 5 µM antisense oligonucleotides were added to the culture medium and 
replenished every 48 h. 
2. Lipofectamine transfection: Lipofectamine working solution was prepared by adding 
1 µl lipofectamine 2000 (Life Technologies) to 50 µl culture medium. 
Oligonucleotide/siRNA working solution was prepared by adding 1 µg 
oligonucleotides/siRNA and 1 nM siGLO green (Life Technologies) to 50 µl culture 
medium. Both working solutions were left at room temperature for 5 min before 
being mixed together gently. The 100 µl mixed solution was then left at room 
temperature for another 15 min before being added to a mature OL culture, and 
incubated in 37°C for 2 h. Transfection medium containing oligonucleotides/siRNA 
and lipofectamine were replaced with normal culture medium after 3 hrs. Mature OLs 
were kept in normal culture medium for another 48-72 h before transfection 
efficiencies were determined by fluorescent microscopy 
3. Viromer transfection: Viromer Blue (Lipocalyx, Halle, Germany) and oligonucleotides 
/siRNA were mixed with transfection buffer to a final concentration of 50 µM and 25 
nM, respectively, and left at room temperature for 10 min before being added to the 
mature OL culture. Transfection medium containing viromer-oligonucleotides/siRNA 
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was replaced after 4 h with fresh culture medium. 
4. RVG9R (Rabies Virus Glycoprotein 9R) procedure: RVG-9R (Peptide sequence: 
YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR) was purchased 
from Bachem, Torrance, CA. Oligonucleotide/siRNA and RVG9R were mixed in a 
ratio of 1:10. One nanomolar siGLO were then added to this mixture.  The solution 
was left at room temperature for 30 min before being added to the culture medium. 
Delivery of oligonucleotide/siRNA to the mature OLs was tested 48 h after the 
procedure with fluorescent microscopy and RT-PCR. 
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Results 
Expression of Tat in vivo does not alter CaMKIIβ expression, but increase CaMKIIβ 
activation 
 We first examined whether expression of Tat altered CaMKIIβ levels in Tat 
transgenic mice. To rule out the possibility that the level of CaMKIIβ may change with 
development, Tat expression was not induced until the mice were 3-month old. Western 
blot results showed that there was no significant difference in CaMKIIβ expression 
between Tat+ and Tat – mice in cortex, cerebellum, striatum or hippocampus (Fig. 4.1A). 
The same samples were also used to test whether CaMKIIβ activation was changed by 
Tat expression. A significantly increased level of CaMKIIβ-T287 phosphorylation was 
detected in all four regions that assessed, indicating increased CaMKIIβ activation by 
Tat expression in these areas (Fig. 4.1B). 
 
Tat induced CaMKIIβ activation in both immature and mature OLs 
Immunostaining results showed that CaMKIIβ was expressed on both immature 
and mature OLs in vitro. In immature OLs, most of the CaMKIIβ was observed in 
processes. In mature OLs, CaMKIIβ was localized in both cytoplasm and major 
processes (Fig. 4.2). We next investigated whether CaMKIIβ was activated as a 
consequence of the Tat-induced [Ca2+]i increase. Both immature and mature OLs 
exposed to 100 nM Tat for 30 min showed significantly increased levels of CaMKIIβ Thr-
287 autophosphorylation, suggesting increased CaMKIIβ activation (Fig. 4.3B). In either 
immature or mature OLs, the expression level of total CaMKIIβ was not affected by Tat 
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treatment (Fig. 4.3A). Further, CaMKIIβ expression level in mature OLs is significantly 
higher than in immature OLs (Fig. 4.3A). 
 
Effects of blocking iGluRs on Tat-induced CaMKIIβ activation 
We next assessed whether blocking iGluRs had any effect on Tat-induced 
CaMKIIβ activation. Immature and mature OLs were treated with MK801 and CNQX 
with or without 100 nM Tat. Western blots showed that CaMKIIβ phosphor-T287 level 
was significantly elevated (~2×) by 30-min Tat treatment. This Tat-induced CaMKIIβ T-
287 phosphorylation was completely reversed by MK801, but only partially inhibited by 
CNQX (Figure 4.4). 
 
Efficiency of CaMKII primer sets 
Existing inhibitors to CaMKIIβ are either non-specific or toxic to OLs in vitro. 
Hence, we tried to silence CaMKIIβ by interrupting its expression in OLs. To be able to 
detect the change of CaMKIIβ transcription in OLs, we first designed primer sets to all 4 
CaMKII isoforms and tested the efficiency of these primer sets. It is known that 
expression levels of different isoforms of the CaMKII varied greatly in murine OLs 
(Waggener et al., 2013). Hence, we used RNAs extracted from cerebral cortex of P2 
ICR mice to test the efficiency of CaMKII primer sets. As Table 5.1 shows, efficiency of 
designed primer sets of CaMKIIα, β, γ, ξ were determined to be 1.98, 1.92, 1.98 and 
2.00, respectively, indicating that RT-PCRs using these primer sets can faithfully reflect 
the mRNA contents in tissues. Same primer sets were then used to determine the 
expression level of CaMKII in cultured OLs.  
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Attempt to delivery antisense oligonucleotide to mature OLs 
Several methods have been tried to deliver the antisense oligonucleotide or 
SMARTpool siRNAs specific to Camk2b gene to D7, mature OLs. We first tried a direct 
feed methodology, where the phosphorothioate-modified oligonucleotide was added to 
the culture medium with a final concentration at 5 µM, in expecting that endocytosed 
oligonucleotide will escape to the cytoplasm and bind to the mRNA of CaMKIIβ, which 
leads to RNase-H mediated degradation of CaMKIIβ mRNA. RT-PCR showed that 
expression level of CaMKIIβ was not changed in antisense oligonucleotide-treated 
culture between 0 - 72 h. We next tried several transfection reagents including 
lipofectamine®, viromer® and the rabies virus glycoprotein 9R (RVG9R). These 
transfection reagent in theory will form a complex with oligonucleotides/siRNA and carry 
them through the cellular membrane. A small fluorescent molecule, siGLO, was co-
transfected with the antisense oligonucleotides/siRNAs, so that the transfection 
efficiency can be evaluated using fluorescent microscopy. Both RT-PCR and 
fluorescent microscopy experiments suggested that none of these methods successfully 
down-regulate expression of CaMKIIβ in mature OLs.  
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Discussion 
Our early studies showed that in mature OLs, Tat-induced [Ca2+]i increases had 
no effect on cell survival, but instead causes a 20 - 25% decrease of the total 
membrane area. The Tat-induced membrane loss can be completely blocked by 
MK801, suggesting that it is mainly mediated by NMDA-Rs. This is consistent with in 
vivo studies from other groups, which reported that Ca2+ influx via ischaemia-mediated 
NMDA-R activation causes OL process degeneration and demyelination (Karadottir et 
al., 2005; Micu et al., 2006). We hypothesized that CaMKIIβ activation may be the 
downstream signaling events that links [Ca2+]i increase and membrane loss in mature 
OLs. Our results showed that 30 min Tat treatment leads to CaMKIIβ activation in 
mature OLs, which can be completely blocked by NMDA-Rs, but only partially blocked 
by CNQX. 
We found that expression of Tat did not change the total amount of CaMKIIβ in 
vivo (Fig. 4.1A), but leads to its activation in all of the four brain regions (cortex, 
cerebellum, striatum and hippocampus) that we sampled (Fig. 4.1B). In the murine 
CNS, CaMKIIβ expression was not restricted to oligodendroglial cells (Zhang et al., 
2014). Hence, we used cell culture to test whether Tat activates CaMKIIβ in OLs. Our 
results showed that Tat induced a ~2-fold increase of CaMKIIβ-T287 phosphorylation in 
both immature and mature OLs. Since >90% of the cells in our culture are from 
oligodendroglial lineage (Table 3.1), and the protein samples were harvested 30 min 
after Tat treatment, it is highly possible that CaMKIIβ activation is a direct result of Tat 
challenge, rather than a secondary effect mediated by other cell types.  
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Several lines of evidences indicate CaMKIIβ as the signaling molecule that 
mediates the Tat effects on OL membrane change. First, Ca2+/CaM activates CaMKIIβ. 
Since the expression levels of other intracellular Ca2+ binding molecule, such as 
Calbindin, are relatively low in OLs (Zhang et al., 2014), Tat-induced Ca2+ influx most 
likely will result in increased levels of Ca2+/CaM complex, which leads to CaMKIIβ 
activation. This is consistent with our Western blot results, which found that CaMKIIβ 
was indeed activated by Tat in both immature and mature OLs (Fig. 4.3B). Second, it 
has been reported that activation of NMDA-Rs promotes an interaction between its 
NR2B subunit and CaMKIIβ, which facilitates CaMKIIβ activation (Bayer et al., 2001; 
Bayer et al., 2006). Coincidently, we found that CaMKIIβ activation by Tat is completely 
abolished by MK801 (Fig. 4.4), indicating the major activator of CaMKIIβ is NMDA-R-
mediated Ca2+ influx. Third, CaMKIIβ has been known to have a structural role besides 
its kinase activity (Hudmon and Schulman, 2002b). At resting state, CaMKIIβ binds F-
actin and stabilizes cytoskeleton structures. Activation of CaMKIIβ by Ca2+/CaM leads to 
a conformational change of its structure and disrupts this interaction, which destabilizes 
actin cytoskeleton (Okamoto et al., 2007; Okamoto et al., 2009). This interaction is 
relevant to OL maturation and myelination because knockout CaMKIIβ leads to 
hypomyelination, while a CaMKIIβ mutant (CaMKIIβA303R) lacks its kinase activity, but 
preserves its actin-binding capacity showed normal myelination (Waggener et al., 
2013). Further, recent studies have suggested that constitutive elevation of [Ca2+]i may 
inactivate the actin binding properties of CaMKIIβ via phosphorylation of S371, which 
leads to collapse of the actin cytoskeleton and affects OL maturation (Martinez-Lozada 
et al., 2014).  
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Based on the results from our experiments and the evidences reported by other 
groups, we proposed the following model for the role of CaMKIIβ in Tat-induced mature 
OL membrane reduction. At resting state, CaMKIIβ binds F-actin and stabilizes the 
cytoskeleton. Activation of NMDA-Rs due to physiological activities leads to a transient 
CaMKIIβ activation. This allows CaMKIIβ to dissociate from F-actin for a short period of 
time and facilitates cytoskeleton growth. Under pathological conditions when Tat was 
secreted by infected cells, interaction between Tat and NMDA-Rs leads to a persistent 
[Ca2+]i increase and prolonged CaMKIIβ activation in OLs, which dissociates CaMKIIβ 
from actin for a long-period of time and destabilizes the cytoskeleton, eventually leading 
to reduction of membrane structure.  
Unfortunately, we are still lacking data that directly links CaMKIIβ to OL 
membrane change. Currently there are no inhibitory drugs that are both specific to 
CaMKIIβ and non-toxic to cells. Multiple attempts have been made to deliver siRNAs 
specific to CaMKIIβ to mature OLs to stop its expression. However, mature OLs are 
very resistant to transfection reactions, and the efficiency of transfection is too low to be 
meaningful to any further experiments (Data not shown). In addition, preventing 
CaMKIIβ expression is not equivalent to inhibiting CaMKIIβ activation. OLs cultured 
from CaMKIIβA303R mutant mice (O'Leary et al., 2006; Lin and Redmond, 2008; 
Waggener et al., 2013) will be a better model to verify our proposed mechanism. In 
these mice, the mutated CaMKIIβA303R preserves the ability of binding and stabilizing 
actin filaments, but was unable to bind Ca2+/CaM, and thus would be predicted to not be 
activated by Tat-induced [Ca2+]i increase. 
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Figure 4.1 
 
 
Figure 4.1 Expression of Tat in vivo does not alter CaMKIIβ expression, but 
promotes CaMKIIβ activation. (A) Western blot using proteins extracted from 4 
different brain regions (cortex, cerebellum, striatum and hippocampus) of the Tat 
transgenic mice showed that in vivo expression of CaMKIIβ in the brain was not 
significantly affected by Tat. (B) Ratio of p-CaMKIIβ/t-CaMKIIβ was significantly 
increased in cortex, cerebellum, striatum and hippocampus in Tat+ mice, suggesting 
that Tat expression leads to increased CaMKIIβ activation in these areas. (*: p<0.05 vs. 
Tat- mice; N=3 individual experiments, t-test) 
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Figure 4.2  
 
Figure 4.2 Expression of CaMKIIβ on OLs in vitro. Immunostaining showed that 
CaMKIIβ was expressed on both immature and mature OLs, and mainly localized in 
cytoplasm and processes (Scale bar = 10 µm) 
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Figure 4.3 
 
 
Figure 4.3 Tat induced CaMKIIβ activation in both immature and mature OLs. (A) 
Western blot results indicated that expression of CaMKIIβ in immature OLs is 
significantly lower than in mature OLs in vitro (*: p<0.05 vs. immature OL), and is not 
affected by Tat treatment. (B) CaMKIIβ activity was significantly upregulated in both 
immature and mature OLs after 1 h Tat treatment (*: p<0.05 vs. vehicle treatment) 
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Figure 4.4 
 
 
Figure 4.4 Effects of blocking iGluRs on Tat-induced CaMKIIβ activation. Immature 
and mature OLs were treated with MK801 or CNQX with or without Tat for 30 min. 100 
nM Tat induced a 2-fold increase of CaMKIIβ T287 phosphorylation when compared 
with vehicle treated OLs. MK801 completely reversed the CaMKIIβ activation in both 
immature and mature OLs, while CNQX only showed a partial effect. (N=4, values are 
presented as mean ± SEM; *p<0.05 vs. control; #p<0.05 vs. Tat treated group; one-way 
ANOVA) 
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Table 4.1 Efficiency of CaMKII primer sets. 
 
Gene	Name CaMKIIα CaMKIIβ CaMKIIγ CaMKIIδ 
Efficiency 1.98 1.92 1.98 2.00 
Y-intercept 19.6 17.14 17.19 22.26 
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Chapter 5 Tat reduces immature OL viability through GSK3β activation 
(This chapter, in part, was in preparation as a manuscript, entitled HIV-1 Tat affects 
oligodendrocyte survival via GSK3β activation, to be submitted to the Journal of 
Neuroscience) 
 
Introduction 
Our previous studies showed that OLs are direct targets of HIV-1 Tat. 
Interactions between Tat and NMDA-Rs and AMPA/KA-Rs elicit a dose-dependent 
increase of [Ca2+]i in OLs, which leads to increased CaMKIIβ activation and reduced cell 
survival in the immature OL population (chapter 3; (Zou et al., 2015)). We thus 
investigated other signaling pathways that are activated by increased OL [Ca2+]i and 
involved in cell death. Since HIV-1/Tat toxicity in neurons has been shown to be 
mediated by abnormal GSK3β activation (Maggirwar et al., 1999; Masvekar et al., 
2015), we hypothesized the existence of similar mechanisms in OLs.  
GSK3 was first identified as a phosphorylating and an inactivating agent of 
glycogen synthase. Two isoforms of GSK3, encoded by two separated genes, GSK3α 
and GSK3β, were originally identified in rat (Woodgett, 1990). Later studies by Mukai et 
al., (2002) found that in the CNS there exists an alternative splice variant of GSK3β, 
GSK3β2. The expression of GSK3β2 is neuron-specific and developmentally regulated. 
Although the exact function of GSK3β2 remains to be determined, silencing GSK3β2 
using siRNA inhibits axon growth in rat cortical neurons, suggesting that it may play a 
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role in neuron morphogenesis (Castano et al., 2010). In contrast, the ubiquitously 
expressed isoform GSK3β1 has been shown to mediate multiple signaling pathways, 
including the conserved Wnt/β-Catenin pathway that regulates cell fate decisions during 
development.  
Different from most kinases, basal activity of GSK3 is relatively high in resting 
cells. Multiple signaling molecules have been shown to regulate activity of GSK3. For 
example, the PI3K/Akt signaling pathway has been reported to phosphorylate the N-
term serine residue of GSK3 (Ser9 in GSK3β and Ser21 in GSK3α) and inhibit GSK3β 
activity (Cross et al., 1995). The p38	mitogen-activated protein kinase (p38MAPK) has 
been shown to phosphorylate the C-term serine residue (Ser 389) of GSK3β, which also 
leads to its inactivation (Thornton et al., 2008). Besides inhibitory phosphorylation, 
activity of GSK3 is also down-regulated when it is bound to other proteins such as 
disrupted in schizophrenia 1 (DISC1) (Mao et al., 2009) and the partitioning defective 
homologue (PAR) complex (Schlessinger et al., 2007). On the other hand, PYK2 
phosphorylates the tyrosine residue of GSK3 (Tyr279 in GSK3α and Tyr216 in GSK3β), 
which increases its substrate accessibility and promotes its activity (Hartigan et al., 
2001). Importantly, studies by Hartigan et al., (1999)  reported that increased [Ca2+]i 
results in up-regulated GSK3 activity, implicating that Tat-induced [Ca2+]i increase in 
OLs may lead to GSK3 activation.  
Activity of GSK3 has been shown to mediate physiological and pathological 
changes in oligodendroglial lineage cells. For example, decreased GSK3 activity leads 
to β-catenin nuclear translocation, which affects OL differentiation and maturation 
(Fancy et al., 2009; Ye et al., 2009). In vivo studies using a range of GSK3β inhibitors 
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also showed that blocking GSK3β activity increased the proliferation and survival of 
OPCs (Azim and Butt, 2011).  The same study further found that besides the pro-
survival effects on OPCs, GSK3β inhibition increased CREB activity, which up-regulates 
OL differentiation and myelination. Thus, GSK3β appear to be a good candidate for 
mediating Tat-induced OL injuries. 
Our studies showed that Tat expression in vivo leads to increased activity of 
GSK3β in multiple brain regions. In vitro, Tat upregulates GSK3β activity and decreases 
cell survival in immature, but not mature OLs, which can be rescued by GSK3β 
inhibitors VPA or SB415286. In addition, we found that expression of GSK3β and 
CaMKIIβ in OLs was developmentally regulated; immature OLs expressing more 
GSK3β but less CaMKIIβ than mature OLs. The Tat-induced elevation of GSK3β and 
CaMKIIβ activities in OLs can be blocked by iGluRs antagonists MK801 and CNQX. 
Further, pharmacologically inhibiting CaMKIIβ activity increases GSK3β activity in both 
immature and mature OLs. Together, our results suggest that the effects of Tat on OL 
viability were mediated through GSK3β activity, and point to CaMKIIβ-GSK3β signaling 
as a potential therapeutic target for OL injuries in HAND patients. 
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Materials and Methods 
Oligodendroglial cultures 
Immature and mature OL cultures were performed as described in chapter 3. For 
Western blot detection of GSK3β and phosphor-GSK3β-S9, O2A/glial progenitor cells 
harvested from 8-day primary mixed culture were plated in a density of approximated 
500,000 cells/dish on poly-L-lysine coated 35-mm dishes. Progenitors were fed with 
differentiation medium [(DMEM supplied with CNTF (10 ng/ml), NAC (5 µg/ml) and 
triiodothyronine (15 nM)] for 2 days or 7 days to reach immature and mature stages, 
respectively. Medium was changed every other day. For repeated measure 
experiments, plating density of progenitors was the same as described in chapter 3. 
 
Viral protein and drug treatments 
OLs were treated with HIV-1 Tat1-86 (1—100 nM), VPA (0.01–1 mM, Sigma), 
SB415286 (0.01–0.05 mM, Sigma), KN-92 (10µM, Tocris), KN-93 (10 µM, Tocris), 
MK801 (20 µM) and CNQX (20 µM), after 2 days in enriched culture. All inhibitors were 
added 30 min before Tat if treated concurrently. Concentrations of drugs were chosen 
as previously reported ((Salter and Fern, 2005; Waggener et al., 2013; Masvekar et al., 
2015)).   
 
Induction of Tat expression in vivo 
 The same Tat-transgenic mice as described in previous chapters (Chapter 2) 
were used here. Three-month old mice (4 Tat- and 4 Tat+) were fed with Dox-containing 
chow ad libitum for 10 days to induce Tat expression. Different regions of the brain, 
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including the frontal cortex, cerebellum, striatum, hippocampus, and midbrain, were 
dissected on ice and stored in -80°C before proteins were extracted for western blotting.   
 
Time-lapse analysis 
Time-lapse analysis was performed as described in chapter 3. In brief, mature and 
immature OLs were cultured in 12-well plates and treated with Tat and/or GSK3β 
inhibitors. Plates were then transferred to the Zeiss Axio Observer Z1 system, and 
placed in the environmental controlled chamber that maintains 37°C temperature and 
supplied with 5% CO2. For each treatment group, ≥50 OLs were randomly picked and 
imaged hourly for 96 h. Data were presented as mean percentage of survival ± standard 
error of the mean (SEM) from at least 4 individual experiments. Two-way ANOVA and 
post hoc Bonferroni’s test was used to compare whether differences between 
treatments were significant (p<0.05). 
 
Live-Dead Assay 
Survival/death of OLs was confirmed using LIVE/DEAD Viability/Cytotoxicity Kit 
(Life Technologies) as previously described (chapter 3). In short, 96 h Tat- or vehicle-
treated OL cultures were washed once with D-PBS and immersed in a working solution 
containing 4 µM EthD-1 and 2 µM Calcein-AM for 30 min at room temperature, before 
mounted on a clean, Fisherbrand Superfrost Plus Gold microscope slide (Fisher), and 
sealed with clear fingernail polish. For each individual treated group, 20 images were 
taken randomly using a Zeiss Axio Observer Z1 microscope with Zen 2012 software 
(Carl Zeiss). Live/dead cells were defined by green (Calcein-AM, Em ~515 nm) or red 
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(EthD-1, Em ~617 nm) fluorescence, respectively, and quantified by the number of 
green/red fluorescent pixels using ImageJ software (National Institutes of Health).  
 
Western Blot 
Western blot procedures are performed as previously described (Chapter 2). 
Primary antibodies specific to phospho-GSK-3β-Ser9 or total GSK3β (Cell Signaling 
Technology), phosphor-CaMKIIβ (Abcam, 1:1000) and total CaMKIIβ (Life 
Technologies, 1:1000) were used at 1:1000 as suggested by manufacturer. Bound 
antibodies were detected by appropriate IRDye secondary antibodies (1:3000, Li-COR, 
Lincoln, NE), and imaged using an Odyssey Imager (Li-COR). Protein bands were 
selected and quantified using Li-COR image studio software. The anti-phospho-GSK3β 
antibody also has weak affinity to phospho-GSK3α (Ser21). However, phospho-GSK3β-
S9 (46kDa) can be easily distinguished from phospho-GSK3α-S21 (51kDa) due to size 
differences.  
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Results 
Effects of Tat on OL survival and GSK3β expression.  
We first examined whether adding HIV-1 Tat to culture medium affects the OL 
viability. The viability of D7, mature OLs was not affected by Tat treatment (Fig.5.1A). In 
comparison, the viability of D2, immature OLs exposed to Tat decreased in a dose-
dependent manner. Approximately 65% OLs treated with vehicle or 1 nM Tat survived 
after 96 h.  This rate dropped to ~55% with 10 nM Tat and further decreased to ~40% 
with 100 nM Tat. The effects of 100 nM Tat on immature OL survival reach statistical 
significance by 24 h, while 10 nM Tat effects become significant at ~ around 60 h (Fig. 
5.1A). A live/dead assay was performed on cells after these experiments (at 96 h) to 
verify the counting results. The Tat (100 nM) treated group exhibited significantly more 
red fluorescent (EthD-1+) and less green fluorescent (Calcein-AM+) cells when 
compared to the control group, indicating less cell survival when exposed to Tat (Fig. 
5.1B). GSK3β signaling pathways have been recently shown to play an important role in 
Tat-mediated neurotoxicity and HIV replication (Kehn-Hall et al., 2011; Zhou et al., 
2013; Guendel et al., 2014). We thus examined whether Tat affects GSK3β expression. 
We did not detect any difference in GSK3β expression between Tat- and Tat+ mice in 
cortex, cerebellum, striatum, or hippocampus (Fig. 5.1C). In vitro experiments using 
pure OL culture showed that expression of total GSK3β in immature OLs was 
significantly higher than in mature OLs (Fig. 5.1D), and these levels were not affected 
by Tat treatment (Fig. 5.1E). 
 
Inhibiting GSK3β activation rescues Tat-induced immature OLs death in vitro.  
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Since Tat did not affect GSK3β expression, we next investigated whether Tat 
affects GSK3β activity, by examining the level of GSK3β-S9 inhibitory phosphorylation 
(Hur and Zhou, 2010). In vivo, expression of Tat leads to significantly decreased ratio of 
phosphorylated GSK3β-S9 over total GSK3β (p-GSK3β/t-GSK3β) in cortex, striatum 
and hippocampus, indicating upregulated GSK3β activity (Fig. 5.2A). The GSK3β 
activity in the cerebellum was not affected. To further elucidate whether Tat regulates 
OL GSK3β activity, cultured OLs were treated with Tat for 24 h. In immature OLs, 10 or 
100 nM Tat leads to significantly increased GSK3β activity when compared with vehicle 
or 1nM Tat treated groups (Fig. 5.2B). The upregulation of GSK3β activity by Tat (100 
nM) can be detected as early as 2h, and persists over 96 h (Fig. 5.2C). In comparison, 
GSK3β activity was not affected by 1 – 100 nM Tat in mature OLs (Fig. 5.2B).  
We further investigated whether blocking GSK3β can reverse the effect of Tat on 
immature OL survival. VPA, a drug that inhibits GSK3β through activation of its 
upstream WNT signaling pathway (Hall et al., 2002), and SB415286, a small molecule 
that competes with ATP on binding GSK3β (Liang and Chuang, 2007) were picked to 
block GSK3β activities in OLs. Efficacy studies showed that 0.1 - 1 mM VPA or 0.01 - 
0.05 mM SB415286 are enough to block GSK3β activities in immature OLs (Fig. 5.2D). 
When VPA (100 µM) or SB415286 (10 µM) were added to immature OLs together with 
Tat (100 nM), both drugs completely reversed the increased GSK3β activity (Fig. 5.2D), 
and immature OL death induced by Tat (Fig. 5.2E).  
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Tat-induced CaMKIIβ activation inhibits GSK3β activity and cell death in mature OLs 
Activities of CaMKIIβ and GSK3β have been known to be regulated by iGluRs-
mediated increase of intracellular calcium (Bayer et al., 2001; Hudmon and Schulman, 
2002; De Montigny et al., 2013). Since the Tat-induced [Ca2+]i  change and cell death 
in immature OL can be blocked by N-methyl-D-aspartate receptor (NMDA-R) antagonist 
MK801 or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate receptor 
(AMPA/KA-R) antagonist CNQX (Zou et al., 2015), we assessed the effects of 
MK801/CNQX on CaMKIIβ and GSK3β activities in Tat-treated OLs. In both immature 
and mature OLs, MK801 completely reversed Tat-induced increase of CaMKIIβ activity, 
while CNQX only partially blocks the upregulated CaMKIIβ activity (Fig. 5.3A). The up-
regulated GSK3β activities in immature OLs were also completely abolished when 
MK801 or CNQX were added concurrently with Tat (Fig. 5.3B). Further, CaMKIIβ 
inhibitor KN93 and its inactive derivative KN92 were added together with Tat to test the 
effects of CaMKIIβ inhibition on Tat-induced GSK3β activation. At both 2 h and 6 h, 
adding KN93 and Tat together significantly increased GSK3β activity in mature OLs. In 
immature OLs, the Tat-induced upregulation of GSK3β activity was further enhanced by 
KN93 (Fig. 5.3C). 
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Discussion 
Previously, we reported that Tat induces increased [Ca2+]i and Ca2+/CaM 
dependent kinase IIβ (CaMKIIβ) activity in both immature and mature OLs, but only 
decreases the cell viability in immature OL population. It is feasible that there may exist 
a causal relationship between the Tat-induced [Ca2+]i increase and immature OL death 
because 1) both effects are Tat dose-dependent, with increased cell death only 
occurring when a significant [Ca2+]i increase was induced by high Tat concentration; and 
2) Tat-induced cell death can be rescued by attenuating [Ca2+]i increase (Zou et al., 
2015). It has been shown that the neurotoxicity of Tat can be rescued by inhibiting 
GSK3β activity (Chao et al., 2014; Masvekar et al., 2015). Since the activities of GSK3β 
are upregulated by iGluR-mediated [Ca2+]i increase (Hartigan and Johnson, 1999), and 
function as a negative regulator of OL proliferation and myelination (Azim and Butt, 
2011), we hypothesized that GSK3β is the downstream signaling molecule that 
mediates the different effects of Tat on immature and mature OL viability. 
Dysregulation of GSK3β activity has been reported to be involved in multiple 
neurodegenerative processes, including HAND (Schifitto et al., 2006; Crews et al., 2009; 
Jacobs et al., 2012). Interestingly, our results showed that GSK3β activity was 
upregulated in cortex, hippocampus and striatum, but not cerebellum, when Tat 
expression was induced in vivo for 10 days (Fig. 5.2A). Cerebellar astrocytes exposed 
to Tat secrets significantly less cytokines/chemokines than astrocytes from cortex or 
spinal cord (Fitting et al., 2010), in accordance with the fact that HIV-related 
neuropathology in cerebellum was rarely reported. Since GSK3β activation was 
regulated by an array of extracellular signals, Tat-induced inflammatory responses in 
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cerebellum may be less potent than other brain regions to stimulate GSK3β activation. 
Alternatively, cerebellum may have a specific mechanism that inhibits GSK3β activation. 
An example of such mechanisms has been described in cerebellar granule neurons 
(CGNs), where depolarization-coupled CaMKII activation inhibits the GSK3β activity and 
promotes neuronal survival (Song et al., 2010). In support of this idea, our experiments 
also found that the activity of CaMKIIβ, the predominant isoform of CaMKII in both OLs 
and CGNs (Burgin et al., 1990; Waggener et al., 2013), was significantly upregulated by 
Tat expression in the cerebellum (Fig. 4.1).  
 
GSK3β is ubiquitously expressed in most CNS cell types, we thus used highly 
purified cell cultures to assess whether Tat regulates GSK3β activities in OLs. Our 
results showed that Tat causes a dose-dependent GSK3β activation in immature, but 
not mature, OLs, parallel with the findings that the viability of mature OLs was not 
affected by Tat (Fig. 5.1A).  MK801 or CNQX, which attenuates Tat-induced [Ca2+]i 
increase and rescues Tat-induced immature OL death (Zou et al., 2015), reversed OL 
GSK3β activation by Tat (Fig. 5.3B), consistent with the idea that activation of GSK3β 
can be caused by iGluR-mediated [Ca2+]i increase (Hartigan and Johnson, 1999). 
Further, VPA and SB415286, two GSK3β inhibitors that block GSK3β activity with 
different mechanisms, both reversed Tat-induced immature OL death (Fig. 5.2E). 
Together, these data strongly suggest a Tat-induced death signaling mechanism where 
interactions between Tat and iGluRs lead to [Ca2+]i increase and GSK3β activation in 
immature OLs, which causes cell death. Studies by other groups have reported that 
GSK3β inhibition prevents mitochondrial cytochrome c release and apoptosis (Maurer et 
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al., 2006; Ngok-Ngam et al., 2013), implying mitochondria dysfunction as the next 
downstream death signaling after OL GSK3β activation. Theoretically, VPA and 
SB415286 also inhibit GSK3α. However, our experiments showed that Tat, VPA or 
SB415286 had no effect GSK3α activity in OLs (Data not shown).  
 
It is intriguing that GSK3β was not activated in mature OLs, since Tat also 
elevates [Ca2+]i in mature OLs (Zou et al., 2015). Cellular calcium signaling is affected 
by many factors such as amplitude and frequency of [Ca2+]i change, source of Ca2+, and 
availability of different Ca2+ binding proteins and downstream components (Mattson et 
al., 1988; Quinlan and Halpain, 1996). For example, mature OLs express higher levels 
of NMDA-Rs than immature OLs (Salter and Fern, 2005; Micu et al., 2006; De Biase et 
al., 2010). Tat-induced NMDA-R activation (Haughey et al., 2001; Deng et al., 2003; 
Kim et al., 2008) may lead to downregulated GSK3β activity in mature OLs, since 
NMDA-R-mediated GSK3β inhibition has been reported (De Montigny et al., 2013). 
Several studies revealed that CaMKII is efficiently activated following NMDA-R-
activation, possibly due to its interaction with the NR2B subunit, which brings it close to 
the NMDA-R channel (Bayer et al., 2006; Lee et al., 2009). Our previous study also 
showed that Tat activates CaMKIIβ, the predominant isoform of CaMKII, in OLs (Zou et 
al., 2015), and inhibition of GSK3β by CaMKIIβ has also been reported (Song et al., 
2010). The results from this study revealed that mature OLs express significantly more 
CaMKIIβ and less GSK3β than immature OLs (Fig. 4.3A), and inhibiting CaMKIIβ 
promotes Tat-induced GSK3β activation (Fig. 5.4C). Collectively, these data strongly 
suggest that the different level of GSK3β activity in immature and mature OLs may 
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attribute to their distinct level of inhibition by CaMKIIβ.  
 
In vivo, elevated CaMKIIβ activity was also observed in the cortex, striatum and 
hippocampus (Fig. 4.1B), hence, it is also intriguing that GSK3β activity was still 
upregulated in these regions (Fig. 5.2A). Compared to CaMKIIβ, expression levels of 
GSK3β are significantly higher in astrocytes (~20×), immature OLs (~6×) and 
endothelial cells (~15×) (Zhang et al., 2014). Our results also showed that Tat did not 
alter the total expression levels of GSK3β or CaMKIIβ in these regions (Fig. 5.1C, 4.1A). 
Activated GSK3β in those cell types may not be inhibited by CaMKIIβ, which could 
result in increased overall GSK3β activity. 
 
WM injuries, such as decreased WM volume (Sarma et al., 2014), increased 
occurrence of abnormal axonal tracts (Gongvatana et al., 2009), and degenerated OLs 
(Gyorkey et al., 1987; Jayadev et al., 2007), contribute to HAND pathogenesis in HIV+ 
patients. Our current findings suggest that upregulated GSK3β activity is essential to 
Tat-induced immature OL death. Hence, interfering with GSK3β activity, by modulating 
NMDA-R and CaMKIIβ activation, might be a potential adjunctive therapy to relieve 
HAND in HIV patients. 
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Figure 5.1 
 
 
Figure 5.1. Effects of Tat on OL survival and GSK3β expression. (A) Tat treatment 
leads to a dose-dependent decrease of immature, but not mature, OL survival (*,#: 
p<0.05 vs. control or 100 nM Tat, respectively, at the same time point.). (B) Results 
from (A) were confirmed by Live Dead assay using Calcein-AM (Live cell, green) and 
EthD-1 (Dead cell, red). Sample images were chosen from vehicle and 100 nM Tat 
treated immature OL groups and stained at 96 h (Scale bar: 10 µm). (C) In vivo, 
expression of Tat has no effect on total GSK3β level in any of the regions examined. (D-
E) In vitro, expression of total GSK3β in immature OLs were significantly (~3 folds) 
higher than in mature OLs (D), and were not affected by Tat treatment within 96 h (E). 
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Figure 5.2 
 
Figure 5.2 Inhibiting GSK3β activity rescues Tat-induced immature OLs death. (A) 
In vivo, Tat expression leads to upregulated activity of GSK3β (decreased ratio of p-
GSK3β-S9/t-GSK3β) in cortex, striatum and hippocampus, but not cerebellum (*: 
p<0.05 vs. corresponding Tat- control). (B-C) Western blots showed that Tat induces a 
dose-dependent upregulation of GSK3β activity in immature, but not mature OLs (B), 
and the upregulated GSK3β activity by 100 nM Tat in immature OLs persists over 96 h 
(C) (*: p<0.05 vs. corresponding control; #: p<0.05 vs. 10 nM Tat). (D) VPA (0.1 – 10 
mM) or SB415286 (0.01 - 0.05 mM) downregulates GSK3β activity in immature OLs, 
and reverses upregulated GSK3β activity by Tat (*,#: p<0.05 vs. Control). (E) Either 
VPA (100 µM) or SB415286 (10 µM) rescues increased immature OL death induced by 
100 nM Tat, while neither VPA nor SB415286 alone affects immature OL viability (*: 
p<0.05 vs. all other groups at the same time point).  
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Figure 5.3 
	
	
Figure 5.3 CaMKIIβ inhibits GSK3β activation in Tat-treated OLs. (A) Tat-induced 
upregulation of CaMKIIβ activity can be completely inhibited by MK801, and partially 
reversed by CNQX (*: p<0.05 vs. Control; #: p<0.05 vs. 100 nM Tat). (B) Either MK801 
or CNQX fully reverses Tat-induced upregulation of GSK3β activity (*: p<0.05 vs. 
Control). (C) In vitro, inhibiting CaMKIIβ by KN93 for 2 h or 6 h significantly promotes 
Tat-induced GSK3β activation (*: p<0.05, vs. Vehicle; #: p<0.05 vs. Tat). 
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Chapter 6 Using co-culture or human brain aggregate model to study OL injury by 
HIV-1/Tat 
 
Introduction 
In vivo, OLs do not exist as an isolated population. Rather, they forms a complex 
network with all the other major cell types in the CNS. Signaling between OLs and 
neurons, astrocytes and microglia have been frequently reported (Bastmeyer et al., 
1991; Schwab and Schnell, 1991). To further assess whether injury mechanisms we 
observed in vitro faithfully reflect HIV pathogenesis in vivo, we used two models: a co-
culture model where OLs are cultured on top of a mixed glial layer and a brain 
aggregate model where dissociated progenitors acquired from mice or human fetal 
tissues were supplied with serum and allowed to aggregate spontaneously.  
Co-cultures of neurons and mixed glia have been used to study the synergistic 
toxic effects of HIV-1 Tat and morphine on neurons (Zou et al., 2011b). In this model, a 
confluent layer of mixed primary glial cells, consisting of mainly astroglia with a small 
percentage of microglia, were cultured initially. Neuronal progenitor cells were then 
plated on the bed layer of glial cells and induced to differentiate into mature neurons in 
defined medium. Treatments of drugs or viral proteins were added in the medium, and 
affected both neurons and the glial bed layer. It has been shown that glial cells treated 
with Tat produce inflammatory cytokines and reactive oxygen species, both of which are 
		 102	
toxic factors to OLs (El-Hage et al., 2006; Eugenin et al., 2007; Zou et al., 2011b). On 
the
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other hand, the glutamate transporter on astrocytes may take up excessive extracellular 
glutamate released by injured cells, thereby preventing the spread of excitotoxic injury 
(Danbolt, 2001; Beart and O'Shea, 2007). Similarly, microglia may be protective to OLs 
by endocytosing cellular components, fragmented nucleotides and degraded peptides 
released from dying/dead cells. In the OL-Glia culture, instead of neuronal progenitor 
cells, we seeded OPCs on top of the glial bed layer and cultured the cells in OL 
differentiation medium. We used this model to answer the question of whether other 
glial cells played a role in Tat-induced OL injury. 
HIV is a human disease, thus, we also used a hBrnAgg model (Pulliam et al., 
1988) with live HIV-1 virus to assess whether the OL injury we observed in mice may 
happen in human. Different from dissociated culture, which usually advances the 
enrichment of certain cell types by a defined set of growth factors or metabolic 
inhibitors, hBrnAggs are formed by the spontaneous aggregation of primary CNS cells 
acquired from dissociated fetal brain tissues. Early studies have shown that the 
hBrnAggs are viable for 60 days in culture and contains approximately 10% OLs, ≥40% 
neurons, and ≥40% astrocytes after 10 days in culture. Importantly, myelin sheaths 
were observed in the hBrnAggs using EM (Pulliam et al., 1988), suggesting that it 
preserves the histological diversity of the brain. Hence we surmised that the hBrnAggs 
could be used to study the effects of HIV on human CNS neuropathologies. 
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Methods and materials 
All the experiments involving live HIV-1 were performed in BSL-2+ viral facility. 
 
OL-Glia co-culture 
To establish OL-glia cultures, mixed glial cultures were prepared first as 
previously described in Chapter 3. In brief, dissociated primary glial cells acquired from 
P0-P2 ICR pups are plated in poly-L-lysine coated, 12-well plate at a density of 200,000 
cells per well and allowed to grow in DMEM supplied with 10% fetal bovine serum for 6 
days. After 6 days, OPCs harvested from 8-day primary cultures were seeded on the 
bed layer of glial cells with a density of 20,000 cells/well and the mixed culture was 
incubated in OL differentiation medium containing T3, NAC and insulin for another 3 
days to allow OPCs to differentiate into immature OLs.  
 
hBrnAgg culture 
Brain tissue (17-wk in age) received from Advanced Bioscience Resources, Inc 
(ABR, Alameda, CA) were mechanically dissociated and gently pushed through two 
nylon mesh pockets with pore sizes of 250 µm and 135 µm, respectively. Cells were 
then washed twice with Rinse Medium (DMEM + 12 g/L glucose, 2.5 mg/L fungizone 
and 50 mg/L gentamicin). A 4 ml cell suspension with a density of 1 × 107 cells/ml was 
added to a 25-ml DeLong flask (Corning) and placed on an orbital shaker with a 
constant rotation speed of 78 rpm in a culture incubator (37⁰C, 10% CO2). The next day, 
1 ml Exchange Medium (Rinse Medium + 15% FBS) was added to the flask. After 3 d, 
the BrnAggs were transferred to 50-ml DeLong flasks; 5 ml of Exchange Medium was 
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added for a total of 10 ml. Medium was exchanged every 3 d for as long as the culture 
was maintained. 
 
PBMCs isolation and infection 
PBMCs were isolated from Leukopak (HemaCare Corporation, Van Nuys, CA) 
using Lymphocyte separation medium (LSM) (MP biomedicals, LLC, Santa Ana, CA). In 
short, leukopak were diluted with PBS-EDTA in a 1:1 ratio before loaded on top of the 
LSM layer (30 ml diluted blood per 12.5 ml LSM) in a 50 ml tube and centrifuged at 
2000 rpm for 30 min at room temperature. Cells were then collected and re-suspended 
in PBS-EDTA (Miltenyi Biotec Inc. San Diego, CA), and treated with ACK lysis buffer 
(Life technologies) for 5 min at room temperature before culture in a T150 flask 
(Corning) in 20 ml HMDM medium [RPMI1640 medium supplied with L-Glutamine (1%), 
fetal bovine serum (10%) and penicillin/streptomycin (1%)] overnight. On the next day, 
cells were collected and re-plated in T75 flasks at a density of 40 million cells per 20 ml 
HMDM per flask. Phytohemagglutinin (PHA-M) was added in the medium to a final 
concentration of 5 µg/mL to activate the PBMCs. After activation, 1 ng HIV-1 p24/ml 
HIV-1Ba-L virus, measured by HIV-1 p24 ELISA (ABL Inc., Rockville, MD), was added to 
the culture medium to infect the PBMCs for 3 days.  
 
Treat hBrnAgg with HIV-1 (R5) or supernatant from HIV-infected PBMCs 
Human BrnAgg were transferred to a 24-well plate and suspended in DMEM 
supplemented with 15% fetal bovine serum overnight. The next day, pure HIV-1Ba-L was 
added to the cells at a final concentration of 1 ng/ml, 10 ng/ml and 100 ng/ml p24. Equal 
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amount of UV-inactivated HIV-1Ba-L were used as a negative control. UV-inactivation of 
HIV-1 was performed by exposing the virus to UV light (3 ml/10 cm2 dish) for 4 min at 
999 mJ/cm2 using a Spectroline UV Crosslinker XL-1000 (Spectronics).  
Three days after PBMCs were infected by HIV-1Ba-L, supernatant was collected 
and passed through a 0.2-µm filter and stored at -80°C. To treat hBrnAggs, an aliquot of 
the supernatant containing 6.77ng/ml p24 was used. Supernatant collected from non-
infected PBMCs were used as negative controls.  
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Results 
Characterization of hBrnAgg 
After 10 days in culture, healthy hBrnAggs appeared as ~1 mm diameter spheres 
with smooth edges. The majority of the inner cells of the hBrnAggs are not stained by 
trypan blue, indicating that they are viable (Fig. 6.1A). To further confirm the cell 
viability, 10-day old hBrnAggs were transferred to a laminin-coated tissue culture dish 
and supplied with DMEM + 15% serum. The aggregates adhered to the bottom of the 
dish within 2 hrs. After 2 days, cells already grew out of the edge of the adherent 
hBrnAggs and can be easily observed using light microscope with a 10x objective (Fig. 
6.1B). Immunostaining using antibodies specific to MAP2, MBP or GFAP showed that 
neurons, OLs and astrocytes were all present in the outgrowing cultures, with GFAP+ 
astrocytes dominating the population (Fig. 6.2). EM examination of hBrnAggs at 30 days 
reveals the subcellular structures inside these cell aggregates. Normal-looking 
mitochondria, and large amount of ribosomes are frequently found (Fig. 6.3 A), 
indicating active cellular activities and protein translation in these cells.  Synaptic 
structures consisting of vesicle-clustering pre-synaptic terminals and post-synaptic 
densities were also found in the aggregates (Fig. 6.3 B). Although myelin structures in 
this model have been described by other investigators (Pulliam et al., 1988), we did not 
find typical, compact myelin structures with periodicity of major dense lines and 
intraperiod lines in our cultures. Western blot did not detect the existence of MBP in the 
hBrnAggs either (Data not shown). However, loosely wrapped membrane structures 
were observed (Fig. 6.3 D&E).  We also noticed groups of dark-pigmented structures in 
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these aggregates that possibly originate from endocytosed dead cells or cell debris (Fig. 
6.3 C).  
hBrnAgg was not infected by HIVBa-L 
In an effort to investigate whether HIV infection leads to human oligodendroglial 
lineage cell injury, we first tried to infect hBrnAggs with HIVBa-L. One-month old 
hBrnAggs were cultured in regular DMEM supplemented with 15% FBS and treated with 
HIV stock containing 1, 10 or 100 ng/ml p24, measured by ELISA. Culture medium was 
changed once at 3rd day and HIV stock was replenished. After 7 days, supernatant of 
the culture was collected and p24 level was measured with ELISA. We did not detect 
any p24 in the supernatant of control- or HIVBa-L- treated hBrnAggs (Data not shown). 
 
High level of HIVBa-L activates GSK3β, but not CaMKIIβ in hBrnAgg 
We next examined whether GSK3β activity was affected when hBrnAggs were 
exposed to HIVBa-L. As Fig. 6.4 shows, hBrnAggs treated with HIVBa-L stock containing 
100 ng/ml p24 showed a significantly increased GSK3β activity when compared with 
control. When hBrnAggs were exposed to HIVBa-L with lower p24 levels (1 or 10 ng/ml), 
GSK3β activity was not significantly affected. On the other hand, CaMKIIβ activity was 
not affected by HIVBa-L (Data not shown).  
 
Repeated measure using OL-Glia co-culture 
Early studies from the lab showed that glia exacerbate the toxic effect of Tat on 
neurons in vitro. We thus used an OL-glia co-culture system to study whether glial cells 
also played a role in OL injuries by Tat. In the co-culture model, OPCs were seeded on 
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top of a confluent primary glial bed layer and fed with OL differentiation medium. Similar 
to the pure OL culture, in ~2 days, most of the OPCs differentiate into immature OLs 
with multiple processes and minimal of production of myelin-like membranes. However, 
it seems that culturing on top of the glia bed layer accelerated the maturation process of 
OLs. At day 5, most of the OLs showed mature morphology with plenty of membrane 
productions (Fig. 6.4). To characterize the percentage of different cell types in the 
culture, immunostaining using antibodies specific to major CNS cell surface markers 
was performed. We found that the majority of cells in the co-culture are O4+ 
oligodendroglial cells (9 - 11%) or GFAP+ astrocytes (85 – 90%). Only 1-2% of all cells 
are MAP2+ neurons or Iba+ positive microglia (Table 6.1).  
We next investigated whether HIV-1 Tat had similar effects on OL viability with 
glial cells present. Co-cultures at Day 2 (immature OLs) or Day 5 (mature OLs) were 
treated with vehicle or Tat and individual cells were followed for 96 h. Presence of glial 
cells greatly reduced the toxicity of HIV-1 Tat on immature OL viability. Although 100 nM 
Tat still leads to significantly more OL death between 72 and 96 h, 1 – 10 nM Tat had 
no impact on immature OL survival when compared to control.  Viability of mature OLs 
is not affected by Tat treatment (Fig. 6.5). As a matter of fact, all the mature OLs we 
tracked survived the 96 h experiment, vehicle-treated or Tat-treated.  
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Discussion 
Our works using high-purity, dissociated mice OL culture had shed some lights 
on how HIV-1 Tat injures OLs. However, there are two limitations that restrict the direct 
link between our findings and the CNS pathogenesis of HIV infection in human. First, 
HIV is a human disease, thus, it is important to understand that cellular responses to 
HIV/viral proteins may diverge significantly between species. For example, mice are 
resistant to HIV infection because the mice CD4 receptor does not bind to HIV envelope 
protein gp120, even though its sequence and structure are similar to human CD4 
receptors (Littman, 1987; Littman and Gettner, 1987; Landau et al., 1988). Studies by 
Seok et al., (2013) also demonstrated that there exist significant differences between 
mice and human in genomic responses to human inflammatory diseases.  Second, cell 
cultures used in our experiments are highly purified and lacking the complex cellular 
composition and architecture of human CNS. Although the purpose of the study was to 
investigate whether Tat possesses direct toxicities to OLs, isolating OLs from other CNS 
cells may have an impact on its gene expression and physiological properties.  
Ideally, the hBrnAgg model would address both issues: it consists of primary 
human cells and contains all major CNS cell types. The original publication reported that 
there are ≥40% GFAP+, ≥40% NSE+, ~10% β-gal+ and ~10% MBP+ cells in the 
hBrnAggs after 10 days in culturing medium (Pulliam et al., 1988). We adopted the 
same procedures and used the same reagents as Pulliam et al., (1988) used to 
reproduce the hBrnAggs culture. The majority of the cells in our hBrnAggs are not 
permeable to trypan blue after 10 days (Fig. 6.1), suggesting that the hBrnAggs are 
formed mostly by live cells. Immunostaining and EM were performed on these 
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aggregates to verify the existence of different cell types and subcellular structures (Fig. 
6.2 & 6.3). At odds with Pulliam et al., (1988), although MBP+ cells were found in the 
culture, we did not observe normal-looking, compact myelin structure in the hBrnAggs. 
Instead, loosely wrapped membrane structures were seen under EM. There are several 
explanations for this. First, most of the primary human cells were differentiated at the 
time of tissue acquisition, and differentiated OLs have been shown to be more 
vulnerable to excitotoxicity than other cell types (Oka et al., 1993; Matute et al., 2007). 
While Pulliam et al., (1988) received their cells within 3 h of tissue procurement, it took 
averagely ~18 h for the cells to be delivered to us after tissue procurement. Hence, 
there may be much reduced amount of OLs at the time we started the culture. Second, 
it has also been reported that factors in culture may facilitate progenitor cells to take the 
astroglial fate (Raff et al., 1983). Consistent with this, when hBrnAgg were allowed to 
attach to the bottom of a laminin-coated dish and grow in the same medium as they 
were cultured in suspension for 2 days, ≥80% of cells were found to be GFAP+. Thus, 
there may be much less OLs and neurons in our hBrnAggs, which greatly decreased 
the probability of OLs locate close enough to an axon and receive the proper signal to 
initiate myelination.  
Although normal myelin was not observed in our hBrnAggs, plenty of loosely 
wrapped membrane structures that mimic un-compact myelin sheath were found. In 
addition, positive MBP immunostaining on adherent hBrnAgg also indicates the 
existence of functional OLs that producing myelin protein. Thus, we tried to infect the 
hBrnAgg with HIVBa-L and investigate whether viral infection had any effect on OLs. We 
did not detect any p24 in the supernatant after 7 days of infection, indicating that the 
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hBrnAggs are not infected by HIVBa-L. This is not surprising because immunostaining 
using antibodies specific to ionized calcium binding adaptor-1 (IBA-1) did not detect 
microglia in the hBrnAggs. Although we cannot completely rule out the possibility that 
there may be a small amount of microglia existing in the aggregates, they may be 
buried in the aggregates and not accessible to the virus. Intriguingly, GSK3β activation 
was still observed in hBrnAggs treated with high concentrations of HIVBa-L (100 ng/ml 
p24). Taking into account that the hBrnAggs are not infected by HIV, GSK3β activation 
may be a result of interactions between cell surface molecule and the HIV envelope 
protein gp120, which has been shown to be a toxic factor to neurons (Podhaizer et al., 
2012), and triggers astroglial inflammatory responses (Pulliam et al., 1993; Benos et al., 
1994; Nath et al., 2000; Zou et al., 2011a). The gp120 effect has also been shown to be 
independent of the major HIV receptor CD4, suggesting that it could affect both 
astrocytes and neurons in the absence of microglia (Kaiser et al., 1990). Since GSK3β 
is universally expressed in all CNS cell types, and its activation by viral protein Tat has 
been reported in neurons and OLs (Maggirwar et al., 1999) we cannot pin down the 
activation of GSK3β to OLs. Future experiments using purified human OLs may answer 
the question whether HIV activates GSK3β in OLs. 
As we mentioned earlier, using hBrnAgg culture as a model to study CNS 
diseases has several advantages. It preserves histological diversity of human CNS and 
is easy to be maintained for long experiment period (up to 60 days). Drug treatment or 
viral infection can be easily realized by addition to the culture medium. The reason why 
our experiments did not meet our expectation is likely the imbalance of cell components 
in our aggregates. One possible improvement to this model is to add human OPCs 
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purchased from ScienCell (ScienCell, Carlsbad, CA) to dissociated brain cells before 
hBrnAggs forms. This may help increase the percentage of oligodendroglial lineage 
cells and facilitate myelination of axons in the aggregates. To further manipulate the 
system, human microglia, even HIV-infected microglia or PBMCs can also be added at 
the time of aggregation. Another way to improve this technique is to use fluorescence-
activated cell sorting (FACS) to separate dissociated cells based on specific cell 
markers, and then use a fixed ratio of different cell types to form the hBrnAggs. In 
theory, hBrnAggs formed this way should be more reproducible. 
We also used an OL-glia co-culture to answer the question whether the existence 
of glial cells have impact on Tat-induced OL injury. As Table 6.1 showed, the co-culture 
contains ~10% OLs, >85% astrocytes and 1-2% microglia. Since glial cells enhanced 
the toxic effects of Tat on neurons, we hypothesized that OL injury by Tat may also be 
exacerbated in OL-glia co-culture. Surprisingly, the existence of glial cells actually 
increased the viability of Tat-treated OLs. All the mature OLs treated with 100 nM Tat 
survived over 96 h experimental periods. For immature OLs, 1-10 nM Tat had no effect 
on cell viability, while 100 nM Tat significantly reduced OL survival only after 72 h. OL 
development and survival in vitro has been known to be dependent on various 
extracellular cues including cytokines/chemokines and neurotropic factors secreted from 
surrounding cells. It has been long known that astrocytes play an important role in 
maintaining environmental homeostasis and provide structural, metabolic and trophic 
support for other cells (Markiewicz and Lukomska, 2006). Recent studies by Pang et al., 
(2013) has shown that astrocyte-conditioned medium protects OPCs from apoptosis 
and significantly increases OL long-term survival. Similar protective role of astrocyte-
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conditioned medium has also been reported to attenuate glutamate-induced neuron 
apoptosis (Lu et al., 2015). Mechanistic studies revealed that the metabotropic 
glutamate receptor 4 (mGlu4) expressed in astrocytes enhances OL viability by 
increasing TGFβ1 expression (Spampinato et al., 2014). Similar OL protection may also 
happen in Tat-induced excitotoxicity in OLs, where the presence of astrocyte leads to 
increased TGFβ1 level in the medium and enhanced OL survival. Since mGlu4s are 
activated under excitotoxic conditions, we did not find significant changes in OL viability 
when co-culture was treated with vehicle (Fig 4.1 vs. Fig 6.5).  
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Figure 6.1 
 
 
Figure 6.1 Cultured hBrnAggs. (A) After 10 days in culture, cells are tightly packed 
and organized into a true sphere of ~1-mm diameter. Trypan blue (dark cytoplasm) 
staining showed that most cells in 10-day aggregates are viable. (B) 10-day old 
hBrnAgg was transferred into a laminin-coated dish and cultured for 2 days. The 
aggregate attached to the bottom of the dish and started to extend its colony. Outgrowth 
of cells around its edge are clearly visible. (Scale bar = 100 nm) 
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Figure 6.2
 
 
Figure 6.2 Immunostaining of adherent hBrnAggs. Sample images are taken at 
areas ~ 700 nm away from the center of the adherent aggregate. MAP2+ neurons, 
MBP+ OLs and GFAP+ astrocytes have all been found to be present in the culture, 
although GFAP+ astrocytes seem to be the dominant cell type. (Scale bar = 10 µm)  
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Figure 6.3 
  
 
Figure 6.3 EM examination of 30-day old hBrnAgg. (A) Healthy looking cells were 
found everywhere, with typical healthy-looking mitochondria, and plenty of ribosomes 
indicating active cellular activities and protein translations in process. (B) Synaptic 
structures consist of both the vesicle-clustering pre-synaptic terminals and the post-
synaptic density were also observed. (C) Groups of dark-pigmented structures, possibly 
formed by endocytosed cell debris or dead cells, were also observed.  (D-E) Membrane 
structures resembling un-compact myelin are often found.   
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Table 6.1. Percentage of cells expressing neuron/glial specific markers at various 
times in OL-Glia co-culture 
 
 O4+ GFAP+ MAP2+ Iba+ 
Day 2  
(n=4, 1618 cells) 
11.64 ± 0.92% 85.69 ± 1.50% 0.99 ± 0.32 % 1.68 ± 0.38% 
Day 5 
(n=4, 1891 cells) 
10.69 ± 0.71% 86.67 ± 0.87% 0.48 ± 0.20% 2.17 ± 0.23% 
Day 8 
(n=4, 1988 cells) 
8.98 ± 0.51% 89.53 ± 0.53% 0.30 ± 0.13% 1.20 ± 0.21% 
 
n: number of individual cultures. 
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Figure 6.4 
 
 
Figure 6.4 HIVBa-L activates GSK3β in hBrnAggs. Thirty-day old hBrnAggs were 
treated with control or HIVBa-L stock with different levels of p24 (1, 10 or 100 ng/ml). 
Western blot results showed that the highest titer of HIVBa-L (100 ng/ml p24) leads to a 
significant increase of GSK3β activity when compared with control. Lower titers of 
HIVBa-L had no effect on GSK3β activity in hBrnAggs (* p<0.05 vs. control; One-Way 
ANOVA with post-hoc bonferroni’s test, n=3). 
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Figure 6.5 
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Figure 6.5 OL-Glia co-culture. Immunostaining using antibodies specific to O4 and 
GFAP showed that OLs can be co-cultured on top of glial cell bed layer. Different from 
pure OL culture, OPCs grow on top of glial cells differentiate faster and show plenty of 
myelin-like membrane production after 5 days. 
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Figure 6.6 
 
 
Figure 6.6 Effects of Tat on OL viability in OL-Glia co-culture. Day 2 or Day 5 OL-
Glia co-culture were treated with vehicle or different concentration of HIV-1 Tat and OLs 
were tracked for 96 h. Mature OL viability were not affected by Tat treatment. For 
immature OLs, 1 nM or 10 nM Tat had no effect when compare to vehicle treatment. 
100 nM Tat leads to significantly less cell survival, but only between 72 to 96 h. (*: 
p<0.05 vs. control, two-way ANOVA followed by post-hoc Bonferroni’s test, N=3)  
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Chapter 7 Conclusions, pitfalls and future studies 
 
WM injury in HIV patients was first discovered almost at the same time when HIV was 
reported. However, the effects of HIV infection on the WM, as well as the mechanisms 
that underlie the injury of OL/myelin, have not yet been systematically assessed 
(Masters and Ances, 2014). Most of the existing studies on WM injuries in HIV are 
descriptive, using modern techniques such as functional magnetic resonance imaging 
(fMRI), diffusion tensor imaging (DTI) and magnetic resonance imaging (MRI). Other 
studies simply attribute these injuries to infection-related inflammatory responses. As a 
recent clinical study showed, various adjunctive anti-inflammatory drugs combined with 
cART does not improve neurocognitive scores of HIV patients when compared with 
cART alone (Tan and McArthur, 2012), suggesting that there must exist factors other 
than inflammation that leads to WM injury. Such factor(s) must have appeared in the 
CNS during an early stage of infection, and continued to exist even when the peripheral 
viral load is reduced to below the clinical detection limit after cART. One candidate of 
such factor(s) is the HIV viral protein Tat, which is expressed across the HIV lifespan, 
and has been reported to be a toxic factor to neurons in the CNS. We thus 
hypothesized that HIV-1 Tat possesses direct toxicity to OLs/myelin. Based on the 
results of all the experiments reported in this thesis, and existing publications (Oka et 
al., 1993; Maggirwar et al., 1999; Salter and Fern, 2005; Okamoto et al., 2007; Alix and 
Fern, 2009; Song et al., 2010; Rumbaugh et al., 2013; Waggener et al., 2013; Fitting et
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 al. 2014; Masvekar et al., 2015), we proposed the following model for Tat-mediated 
injuries in immature and mature OLs. In immature OLs, interaction between Tat and 
NMDA-Rs activates NMDA-Rs and leads to Ca2+ influx. Since CaMKIIβ binds NR2B and 
co-localizes with NMDA-Rs, the NMDA-R-mediated Ca2+ influx efficiently activates 
CaMKIIβ, which recruits and activates AMPA-Rs, and leads to more Ca2+ influx and 
persistent [Ca2+]i increase. This elevated [Ca2+]i  then activates GSK3β, triggers 
downstream death signaling pathways, and eventually results in cell death. In mature 
OLs, Tat also activates NMDA-Rs and leads to Ca2+ influx and CaMKIIβ activation. 
Since NMDA-Rs are mostly located at processes and myelin-like membranes, activated 
CaMKIIβ dissociates from actins and destabilizes the cytoskeleton, resulting in 
membrane disintegration. In addition, activated CaMKIIβ also migrates to the cell soma, 
where it recruits and activates AMPA/KA-Rs, which leads to more Ca2+ influx. 
Meanwhile activated CaMKIIβ also phosphorylates GSK3β-S9 and inhibits its activation, 
thus protects mature OLs from death (Fig 7.1). 
We used the Tat-transgenic mice to examine whether in vivo expression of Tat in 
the CNS had any effects on WM.  One benefit of the Tat-transgenic mice that we used 
is the temporal control of Tat expression by DOX. Since active myelination during 
mouse development happened in the first month after birth, we did not feed the mice 
with DOX until they were 3-months old. Thus, the abnormality of OLs and myelin we 
observed, as well as the reduced expression of myelin protein MBP and MAG, are likely 
to be caused by Tat-induced injury. Restricted by the length of experiments and amount 
of mice, all the subcellular structure change observed by EM are descriptive. Adding 
quantitative EM studies such as investigating whether the g-ratio of WM tracts is 
		 125	
affected by Tat expression can strengthen this study, as we have observed groups of 
hypomyelinated axons in Tat+ mice.  
To answer the question whether Tat had direct toxicity on OLs, we used a highly 
purified murine OL culture. Based on our immunostaining experiments, this culture 
contains >96% O4+ OLs within the first 5 days, and >90% O4+ OLs between day 6 and 
day 10. Although this model can greatly reduce the impact of other CNS cell types, we 
cannot completely rule out the possibility that other cell types, mainly astrocytes, may 
still affect the results we observed, especially at later time points. Using this model, we 
found that viability of mature OLs was not affected by 100 nM Tat. Consistently, early 
studies by Hauser et al., (2009)  using the same transgenic mice did not find an 
increase of TUNEL staining in APC+ mature OLs after Tat induction, suggesting that the 
Tat expression in vivo does not affect mature OL viability. However several recent 
studies reported that astrocytes protect OLs from iGluR-mediated excitotoxicity (Pang et 
al., 2013; Lu et al., 2015). Our repeated measure experiments using OL-glia co-culture 
also showed that glial cells attenuated the effect of Tat-induced OL death. Thus, the 
conclusion that Tat does not affect viability of mature OLs is still debatable. Using 
fluorescence-activated cell sorting (FACS) technique to isolate olig2+ OPCs from 
primary mixed glial culture may be a way to acquire close to 100% pure mature OL 
population, which in theory can give a definitive answer whether Tat directly affects 
mature OL viability.  
We observed that Tat leads to persistent [Ca2+]i increase in both immature and 
mature OLs, which can be attenuated by either MK801 or CNQX. Interaction between 
Tat and the NR1 subunit of NMDA-Rs has been documented (Rumbaugh et al., 2013). 
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It is thus proposed that this interaction causes a conformational change of the NMDA 
receptor, which leads to its activation. On the other hand, physical binding between Tat 
and AMPA/KA-Rs has never been reported. Although other studies also reported that 
Tat activates AMPA/KA-Rs (New et al., 1998), the mechanism remains unclear. 
AMPA/KA-Rs-mediated Ca2+ influx has been shown to usually lead to activation of 
various death pathways in OLs (Stys, 2004; Matute, 2010; Domercq et al., 2011; 
Matute, 2011), while to our best knowledge, the OL death pathways triggered by 
NMDA-R activation have not been seriously studied. Thus, understanding how Tat 
activates AMPA/KA-R may have important therapeutic significance. As mentioned in 
chapter 3, studies by other investigators have shown that CaMKII recruits AMPA-Rs 
from intracellular vesicles to cytoplasmic membranes, and increases the likelihood of 
channel opening by phosphorylating Ser-831 of AMPA-R GluA1 subunits (Milstein and 
Nicoll, 2008; Derkach, 2011; Kristensen et al., 2011). Since NMDA-R-mediated 
CaMKIIβ activation has been observed in OLs treated with 100 nM Tat, it is possible 
that AMPA/KA-R activation is a downstream event following Tat-induced NMDA-R and 
CaMKII activation. Measuring AMPA/KA-R current in OLs while inhibiting NMDA-R 
and/or CaMKII can test this hypothesis. Since the duration of these experiments should 
not go beyond 1 h, existing CaMKIIβ inhibitors such as KN-93 can be used for this 
purpose.  
It is really interesting that inhibiting both NMDA-Rs and AMPA/KA-Rs can not 
completely block Tat-induced [Ca2+]i increases. Since our Ca2+ imaging experiments 
found that the primary source of [Ca2+]i increase is extracellular Ca2+, most of the 
inhibitors we tested target OL surface molecule or channels. Internal Ca2+ stores such 
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as mitochondria and endoplasmic/sarcoplasmic reticulum also play important role in 
maintaining intracellular Ca2+ homeostasis. Fitting et al., (2014) had reported that the 
interaction between Tat and NMDA-Rs leads to Na+ influx, which reverses Na+/Ca2+ 
exchange and triggers mitochondrial Ca2+ release. The same mechanism may also 
exist in OLs. We found that using dantrolene to block ryanodine receptors (RYRs) had 
no effect on Tat-induced [Ca2+]i increase. However, it has been reported that dantrolene 
had no effect on the RYR2 isoform (Zhao et al., 2001). Thus, using inhibitors such as 
ryanodine that blocks all 3 isoforms of RYRs can tell whether Ca2+-induced-Ca2+ release 
from internal stores contributes to Tat-induced [Ca2+]i  increases. It is well established 
that Tat can be taken up by cells via macropinocytosis (Wadia et al., 2004; Kaplan et 
al., 2005). Using biotin-conjugated Tat1-86, we found that Tat enters the OL cytoplasm 
within an hour (Fig 7.2). Hence, it is also plausible that Tat may interact with surface 
molecules or channels on the internal Ca2+ store and results in Ca2+ release. Adding 
cyclopiazonic acid (CPA) to deplete internal Ca2+ stores right before assessing Tat 
induced OL [Ca2+]i change can be a future experiment to tell whether Ca2+ release from 
internal stores plays a role in Tat-induced [Ca2+]i increases in OLs. 
It is generally accepted that resting CaMKIIβ bundles and stabilizes the actin 
cytoskeleton. Transient activation of CaMKIIβ relaxes the cytoskeleton, promotes actin 
polymerization and CaMKIIβ recruitment, and favors cytoskeletal growth. This model 
has been shown in both synaptogenesis (Okamoto et al., 2007) and OL maturation 
(Waggener et al., 2013). Based on this theory, we proposed that prolonged CaMKIIβ 
activation by NMDA-R-mediated Ca2+ influx leads to destabilization of the actin 
cytoskeleton and membrane disruption in mature OLs. Although our experiments 
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unambiguously showed that NMDA-R activation results in CaMKIIβ activation, direct 
proof that links CaMKIIβ activation and membrane reduction are lacking. All the existing 
CaMKIIβ inhibitors are either non-specific or highly toxic to OLs (usually kills cells within 
10 h).  Since the membrane reduction in OLs is a long-term phenomenon (in our 
experiments paradigm, it is observed at 24 and 48 h), pharmacologically blocking 
CaMKIIβ activation is unrealistic. Although an ON-TARGETplus SMARTpool siRNA 
specifically against mice Camk2b was commercially available, we failed to find an 
effective way to deliver the siRNA into mature, adherent OLs. Plus, hypomyelination in 
ventral spinal cord has been reported in CaMKIIβ KO mice, suggesting that silencing 
the CaMK2b gene itself already had an impact on the actin cytoskeleton. Thus, 
inhibiting CaMKIIβ expression may also not be an ideal way to assess whether mature 
OL membrane reduction is the result of prolonged CaMKIIβ activation. As mentioned in 
chapter 4, a repeated measure experiment using OLs from CaMKIIβA303R mice will be 
the best way to investigate this question. The CaMKIIβA303R mutant retains its ability to 
bundle F-actin, but loses its Ca2+/CaM binding capacity. Based on our proposed model, 
Tat-induced [Ca2+]i increase should have no effect on OL membrane area since 
Ca2+/CaM cannot bind and activate CaMKIIβA303R, and promotes its release from actin 
cytoskeleton.   
Most of our experiments are done in mouse cells. Since HIV is a human disease, 
we used an hBrnAgg model to try to verify our findings in human cells. We speculated 
that the hBrnAgg model would serve our experiments best because 1) it mimics the in 
vivo cell composition with the presence of all major CNS cell types; 2) myelination has 
been observed in the model by other investigators, thus fulfilling the need of studying 
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the effect of HIV/Tat on both OLs and myelin; and 3) the hBrnAgg model can be 
maintained for a long period of time (up to 60 days), making it a good model to study the 
long-term effects of HIV/Tat.   
Our immunostaining experiments suggested that there are far less OLs in the 
aggregates than we expected. Under EM, plenty of synaptic structure, both symmetric 
and asymmetric, were observed in the hBrnAgg. However, cells with typical mature OL 
characteristics, including dark cytoplasm and nucleus, elongated, thin strands of 
endoplasmic reticulum; numerous mitochondria, and stacks of Golgi apparatus, were 
rarely found. Although we detected expression of myelin protein MBP in the outgrowth 
of aggregate cultures, we did not detect MBP directly in the hBrnAggs, and compact 
myelin was also never observed in these aggregates under EM. As we mentioned in 
chapter 6, a possible explanation is that too much time (>18 h) has passed between 
tissue procurement and the initiation of culture. OL lineage cells are known to be 
vulnerable to excessive extracellular glutamate, inflammatory cytokines and reactive 
species (Oka et al., 1993), all of which were produced during the procurement 
procedure. Hence, the brain tissue that we received may only have a small amount of 
surviving OLs, which results in a relatively rare probability that OLs are located in 
proximity to axons. It has been shown that in vitro OLs will ensheath anything within its 
reach that feels like an axon (Rosenberg et al., 2008). However, to a great extent 
myelination is determined by axonal activity-dependent release of glutamate, 
adenosine, neuregulin and BDNF, which promotes OL NMDA-R expression and 
activation, and facilitates myelin membrane compaction (Demerens et al., 1996; 
Stevens et al., 2002; Lundgaard et al., 2013). Consistently, we found plenty of loosely-
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wrapped myelin-like membrane in the hBrnAgg under EM, indicating that membranes 
produced by OLs lacking signaling for myelin compaction. Hence, future studies using 
this model should pay attention to the composition of different cell types in the hBrnAgg. 
As proposed in chapter 6, using FACS technique to sort dissociated brain cells, and use 
fixed ratio of different cell type to form the hBrnAgg may be a good strategy. Not only it 
may lead to better reproducibility of experiments, but also by this way investigators can 
further adjust the system to meet requirements of different studies. 
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Figure 7.1 
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Figure 7.1 Proposed model for the direct effects of HIV-1 Tat on OLs. In immature 
OLs, interactions between Tat and NMDA-Rs (1) leads to Ca2+ influx (2), which binds to 
CaM (3) and activates CaMKIIβ (4). Activated CaMKIIβ recruits AMPA-Rs to the cell 
surface (5) and phosphorylates AMPA-Rs at S831 (6), which increases the conductance 
of AMPA-Rs and leads to more Ca2+ influx (7), and results in an overall [Ca2+]i elevation. 
This increased [Ca2+]i dephosphorylates and activates GSK3β (8), and activated GSK3β 
may lead to increased DNA damage, ER stress and hypoxia and inhibition of 
prosurvival transcription factors such as CREB and heat shock factor-1, which 
eventually resulted in cell death.  Similarly, in mature OLs, Tat-NMDA-R interaction (1) 
leads to Ca2+ influx (2), and CaMKIIβ activation by Ca2+/CaM complex (3,4). Activated 
CaMKIIβ relaxed its interaction with F-actins and dissociated from actin cytoskeleton 
(4), which caused the cytoskeleton destabilization and the reduction of the area of 
myelin-like membrane (5). Dissociated CaMKIIβ may move to cell body, where they 
recruits and phosphorylates AMPA-Rs, which results in increased [Ca2+]i, just as what 
happened in immature OLs (6,7,8). In the cell soma of mature OLs, incoming activated 
CaMKIIβ also phosphorylates GSK3β at Ser-9, which inhibits GSK3β activation and 
prevents activation of death signaling pathways in mature OLs.  
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Figure 7.2 
 
 
Figure 7.2 Immunostaining of 1h Biotin-conjugated Tat treated OLs. 
Immunostaining using antibodies specific to O4 and biotin showed that Biotin-
conjugated Tat presents in the cytoplasm of both immature and mature OLs after being 
added to the culture medium for 1 h. 
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